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ABSTRACT 
Epithelial ovarian cancer (EOC) has the highest mortality rate among all gynecological 
malignancies. Early detection and intervention remain key to patient prognosis fueling the 
search for reliable biomarkers. MicroRNAs (miRNAs) are small non-coding RNAs that play a 
crucial regulatory role within the cell and their dysregulation is associated with many diseases 
including cancer. In this study, using several well-characterized human EOC cells lines, EOC 
patient tissue and serum samples, and an in vivo mouse model we investigated the role and 
mechanism of miR-590-3p in promoting ovarian cancer. Our findings indicate that miR-590-
3p levels were elevated in both clinical ovarian tumor samples, as well as in the blood serum 
of the same patients than in subjects with benign gynecological disorders. Overexpression of 
miR-590-3p in multiple EOC cells led to an increase in cell proliferation, migration, invasion, 
colony formation, and spheroid formation. In addition, injection of cells overexpressing mir-
590 precursor into nude mice increased the dissemination of the tumor nodules, and formed 
larger tumors compared to control groups. cDNA microarray for cells overexpressing mir-590 
revealed Forkhead box A2 (FOXA2) and Versican (VCAN) as one of the top downregulated 
and upregulated genes, respectively. Interestingly, ChIP-qPCR revealed that FOXA2 binds to 
VCAN promoter, and overexpression of FOXA2 reduced, while knockout of FOXA2 increased, 
VCAN mRNA and protein levels. Moreover, luciferase assay confirmed that miR-590-3p is 
directly targeting the 3’UTR of FOXA2 and cyclin G2 (CCNG2) to suppress their expressions. 
In addition, silencing of CCNG2 mimicked the effect of miR-590-3p and induced cell 
proliferation, migration and invasion, while CCNG2 overexpression reversed this phenotype. 
In addition, mir-590 precursor increased the β-catenin activity in TOPflash assays, whereas, 
knockdown of β-catenin blocks the effect of mir-590 on spheroid formation. Altogether, our 
results demonstrate that miR-590-3p has tumor-promoting effects in EOCs via targeting 
FOXA2 and CCNG2 which leads to induction of VCAN and β-catenin signaling.     
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I. OVARIAN CANCER 
Ovarian cancer comprises three major categories namely: epithelial, germ cell and 
stromal cancers. Epithelial ovarian cancer (EOC) is the deadliest and the most common ovarian 
type which accounts for almost 90% of all reported cases [1]. Therefore, the focus of this study 
will be on EOC and its subtypes. The low survival rate for women with EOC results from the 
inability to detect the disease at an early curable stage, the vagueness of accompanying 
symptoms, the lack of effective treatment for the advanced stages and from our incomplete 
understanding of the mechanism by which EOC develops. All these factors contribute to make 
EOC the most lethal cancer among all gynaecological malignancies, and the 5th leading cause 
of cancer death in women [2].  
I. 1. Etiology and Epidemiology 
In 2018, an estimated 22,240 new ovarian cancer cases and 14,070 deaths were reported 
in the United States [3]. In Canada, each year, 2800 Canadian women will develop EOC, of 
which 1800 will die as a direct consequence of disease [4]. This rate ranks ovarian cancer as 
the fifth leading cause of cancer-related death among women [5]. Despite the ongoing efforts 
to develop treatment regimens and effective surgery, the overall rate of survival for ovarian 
cancer is still relatively low, mainly due to late stage diagnosis [6, 7]. The success rate of 
conventional ovarian cancer therapies, such as chemotherapy and cytoreductive surgery, can 
be as high as 90% if the disease is diagnosed at an early stage. The late-stage diagnosis of 
ovarian cancer is often due to minimal symptoms of the disease that are often confused with 
gastrointestinal problems [7, 8].  As ovarian cancer affects a large number of women 
worldwide, it is highly important to understand the molecular mechanism by which ovarian 
cancer develops and progresses in order to improve therapeutic efficacy and patient outcomes. 
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I. 2. Stages and Grades of Epithelial Ovarian Cancer 
EOC stage is determined by the level of cancer dissemination within the patient’s body.  
Identifying the correct cancer stage is vital for choosing proper treatment methods and 
prognosis [9]. Generally, four different stages of ovarian cancer are described. In stage I, the 
tumor is confined to the ovaries and is characterized by the lack of ascites formation, which is 
the accumulation of fluid in the abdominal cavity as a secondary result of cancer progression. 
During stage II, malignant cells from the primary tumor begin to metastasize to other pelvic 
tissues, like the uterus and fallopian tubes, via the ascites fluid, which also contains cytokines 
and growth factors that sustain tumor progression [10-12]. Stage III is marked by the extension 
of the tumor to the omentum or the visceral peritoneum, yet they are still limited to the true 
pelvis. Stage IV begins when tumors progress further, infiltrate one or both ovaries, and 
metastasize into distant organs [13]. Cancer stage is a key factor in prognosis and is directly 
correlated with survival rate as it declines rapidly from 93% with Stage I, to as low as 19% 
with Stage IV [14].   
EOC is classified into grades according to the degree of cell differentiation of malignant 
cells [13]. Grade I tumor cells are well differentiated, grade II tumors are little differentiated, 
while grade III and IV tumors are poorly differentiated [13]. In general, tumors showing a high 
degree of cell differentiation resemble and behave similarly to the surrounding healthy tissues 
[13]. 
 
I. 3.  Histopathological Subtypes of EOC 
In the past, the majority of research identified EOC as one disease. However, it is well 
established now that ovarian cancer is a heterogeneous disease. Recent studies classify ovarian 
cancer as several distinct diseases rather than one disease with different subtypes [15]. The 
focus of this review will be on EOC and its different subtypes which include: serous, 
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endometrioid, clear cell and mucinous. Each subtype has a distinct molecular profile, prognosis 
and progression models.  
I. 3.1 Serous Carcinoma 
I. 3.1.a. High-Grade Serous Carcinoma 
High-grade serous carcinoma (HGSC) is the most common subtype, accounting for about 75% 
of EOCs. A pathologic examination of HGSC reveals solid or papillary growth with grooves 
and tumor cells that are characterized by rapid cell proliferation, abnormal cell nuclei with 
variability in size and shape. Generally, HGSCs is accompanied with disseminated tumor 
masses in the omentum, ovaries, and other intra-abdominal locations with or without ascites. 
Only less than 5% of patient cases can be diagnosed in the first stage while the cancer is still 
contained within the ovaries [16, 17]. Due to the late detection of HGSC, it is challenging to 
study any earlier events of this subtype. However, recent studies suggested that HGSC 
originates from the fallopian tube epithelium rather than from the ovary [16, 17]. Also, the 
genetic instability of HGSC could be due to frequent mutations in BRCA2, BRCA1, and TP53 
tumor suppressor genes. 
I. 3.1.b. Low-Grade Serous Carcinoma 
Low-Grade serous carcinoma (LGSC) is characterized by the appearance of papillary 
structures, uniform small nuclei, and low mitotic activity. LGSCs are less common than HGSC 
[17]. Patients with LGSC are often diagnosed at an early stage (usually stage I), and tend to 
have a higher survival rate. However, patients with advanced stage LGSC have a lower survival 
rate [18-20], likely due to the relatively high chemoresistance of the recurrent LGSC compared 
to HGSC [21]. Molecularly, LGSC is often marked with distinct mutations in KRAS, BRAF 
and/or ERBB2 [22, 23].  
Despite the similar naming, LGSC rarely develops into HGSC, and the two serous 
carcinomas mostly do not have any overlap in mutational patterns [23]. Furthermore, LGSC is 
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likely to be present in premenopausal women around the age of 45-50, compared to HGSC, 
which usually affects women around the age of 60 and older [4]. 
 
I. 3.2. Endometrioid Carcinoma 
Endometrioid Carcinoma (EC) is one of the two major subtypes of ovarian carcinoma 
that has a well-defined endometriosis (ectopic endometrial tissue) association [24-26]. 50% of 
patients with EC are diagnosed in stage I of which, 15% percent of the cases affect both ovaries 
[27]. The early intervention of EC is usually effective as patients diagnosed with stage I cancer 
are likely to have promising outcomes [28]. However, when detected at later stages, the overall 
5-year survival is poor [28]. There is a number of genes that are typically mutated within the 
endometrioid carcinomas including: the characteristic mutation in CTNNB1, as well as in 
KRAS, PPP2R1A, ARID1A, PIK3CA and  PTEN [29]. 
 
I. 3.3. Clear Cell Carcinoma 
Clear cell carcinoma (CCC) was given this name due to the abundance of the clear 
intracytoplasmic glycogen. Like the endometrioid carcinoma, the majority of CCC is detected 
in stage I. However, studies showed a fairly unfavourable outcome prediction for women 
diagnosed with this type of tumor [30-32]. CCC is the second type of ovarian cancer that is 
related to endometriosis and is often associated with either benign tumors known as clear cell 
adenofibroma or with cysts. Nevertheless, CCC developing from adenofibroma is less likely 
correlated with endometriosis compared to the cystic CCC [33]. About 50% of CCC have 
mutations in ARID1A and approximately 36% contain PIK3CA mutations [34, 35]. In addition, 
most CCC cases also have mutations, but at a lower frequency, in PPP2R1A, PTEN, KRAS, 
and TP53 [36-38]. 
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I. 3.4. Mucinous Carcinoma 
Benign mucinous carcinoma (MC) is the least common type of ovarian carcinomas, and 
represents approximately 12% of the total ovarian tumors and if diagnosed early, have a high 
survival rate [39, 40]. Most ovarian MC cases are the result of metastases initiated in distal 
locations like biliary and gastrointestinal tracts or the pancreas [41-45]. MC is usually glandular 
in shape and composed of stratified columnar cells that are characterized by having basally 
located pale-staining mucin, and nuclei at the apical cytoplasm [45, 46]. However, it can 
sometimes be difficult to differentiate metastatic from primary MCs as many mucinous 
carcinomas show intestinal-type differentiation evidence [46]. In approximately 50% of 
invasive MC, both TP53 and KRAS  genes are mutated within the same tumors [47].  On the 
other hand, in 19% of them, ERBB2 is amplified [48]. Expectedly, KRAS mutation 
and ERBB2 amplification can be linked to survival rate alteration [48]. The lack of information 
on other molecular alteration frequency in mucinous carcinomas makes this type of cancer 
difficult to diagnose. 
 
I. 4. Origin of EOC Subtypes 
Although they are all called ovarian cancers, the origin of different EOC subtypes has 
been debated. For nearly half a century, it was widely believed that EOC develops from the 
ovarian surface epithelium (OSE), or from the coelomic epithelium, which is a single layer of 
mesoepithelial cells with multipotent properties that covers the ovarian surface [49]. More 
recently however, accumulating evidence suggests that not all these subtypes originate from 
the ovaries, and that they may originate from other tissues such as fallopian tubes or 
endometrial-type epithelium [49, 50] (Figure 1.1). It has been reported that the most common 
form of EOC, serous ovarian cancer, originates from the fallopian tube epithelial cells, 
particularly from the secretory cells at the fimbriated end of the fallopian tube [51].  Moreover, 
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recent experiments performed on mice, proposed that serous carcinomas may occur in cell 
populations that have stem-cell-like properties found in areas covered with peritoneal 
mesothelium, OSE and fallopian tube epithelium [52, 53]. 
On the other hand, other studies have shown that up to 50% of the EC and CCC cases 
are associated with endometriosis and that patients with endometrioses are significantly more 
susceptible to ovarian cancer [54]. The mechanism by which endometriosis develops is still 
unclear. It was believed that implantation of endometrial tissues may take place outside the 
endometrium walls through retrograde menstruation [55]. However, it is now believed that 
endometriosis arises from endometrial stem cells or progenitor cells that differentiate after 
menarche [56].  In other cases, genetic and morphological studies showed a transition from 
endometriotic cysts to EC or CCC [33, 57, 58]. The common mutational range of ovarian 
cancers associated with endometriosis and uterine EC are likely to have a common origin that 
is attributed to the endometriosis.  
There is a lot of uncertainty about the origin of the MC subtype. This is probably 
because the intestinal cell-like differentiation is not typical of epithelia in the female genital 
tract and that only a small subset of MC show endocervical differentiation suggesting a 
Müllerian origin [6]. However, studies carried out recently concluded that MC may be derived 
from multiple layers of ovarian germ cell tumors, known as teratomas [59, 60]. This least 
common subtype of EOC may be the only ovarian cancer type that has been proven to be 
developed from ovarian cells [61].     
In summary, only a small portion of ovarian carcinomas has been proven to originate 
in the ovaries. This paradigm shift has moved the focus from the ovaries as the sole cause of 
all ovarian carcinomas into also considering other neighbouring organs [62]. In addition, 
understanding the origin of these EOC subtypes is important to the development of better 
diagnosis and detection techniques and treatment options to help improve patients’ prognosis. 
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Figure 1.1: Suggested cellular origins of ovarian carcinomas. Studies suggest that several 
ovarian cancer subtypes have an origin outside the ovaries. The progression and origins of 
these carcinomas remain to be confirmed. In pictures, white arrows indicate ovarian surface 
epithelium (OSE), and black arrows indicate fallopian tube epithelium (FTE). Reprinted with 
modifications from [6] and photographs of pathology slides reprinted from Kathleen Cho 
(2016) with permission. 
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I. 5. Molecular and Genetic Abnormalities of EOC Subtypes 
Modern analytical procedures have allowed researchers to perform in-depth studies on 
ovarian cancer using genomic and wide transcriptome screens. In addition, it is now possible 
to perform metabolic and proteomic screens [63]. The introduction of these new methods 
allowed better analysis of EOC molecular markers, protein interactions, and metabolism [64].  
In general, cancer develops either due to the accumulation of genetic modifications or 
other molecular defects, but most genetic modifications result in anomalous cellular functions 
such as immune evasion and uncontrolled cell division [65]. Although some inherited 
mutations through the germline may lead to cancer development, the disease sequentially 
develops through an acquired somatic mutation in the site of origin. These mutations in genes 
encoding proteins that can cause either activation of oncogenes or inactivation of tumor 
suppressors. (Table 1).   
 
I. 5.1. Inherited Mutations 
Patients with a family history of ovarian cancer are more likely to be at higher risk for 
developing it. Mutations in BRCA1 and BRCA2 genes are typical ovarian cancer indicators, 
and they account for almost 15% of all cases of ovarian carcinomas [66]. In a study on Jewish 
Ashkenazi women, BRCA1 and BRCA2 were responsible for 40-50% and 20-30%, 
respectively, of ovarian cancer total lifetime risk [67]. These mutations also contribute to about 
5-10% of acquired breast cancers and 20-25% of the inherited ones [68, 69]. However, BRCA1 
and BRCA2 are not the only genes associated with ovarian cancer, and others include: MLH1, 
EPCAM, PMS2, MSH1, MSH6 and TP53 [70]. Most of these vital genes are involved in the 
DNA repair process. Therefore, women with a mutation in one or more of these genes are at a 
higher risk of developing ovarian carcinomas [71]. 
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I. 5.2. Acquired Mutations 
More than 95% of HGSC patients are diagnosed with a mutation in TP53 [72-74]. 
Despite the fact that most ovarian serous tumors grow as de novo high-grade lesions with TP53 
modification, it is now believed that the tumors may also arise from an already established low-
grade tumor. [75]. A control experiment shows that the majority of these cases were not 
identified as HGSC [76]. In addition, previous genetic studies conducted on serous carcinomas 
were not accurate. This is due to the inclusion of other subtypes of non-serous ovarian 
carcinomas.  
Almost one-third of the HGSC cases are characterized by having somatic mutations in 
BRCA1 and BRCA2 [77]. A statistical study conducted recently on putative homologous 
recombination in gene mutation, showed rare somatic disorders in BRIP1, RAD51C and 
CHEK2 in the advanced stages of HGSC [78]. The Cancer Genome Atlas (TCGA), carefully 
sequenced exomes of more than 300 cases. It was found that almost all these cases have 
mutations in BRCA1, BRCA2 and TP53. In addition, FAT3 and NF1 were also identified as rare 
mutated genes in approximately 3% of the cases studied. Similarly, PIK3CA, MYC, CCNE1 
and KRAS were abundantly expressed suggesting that these particular genes can be used as 
markers to help in early prognosis [78]. Additionally, deletions in other genes such as PTEN, 
ZBTB7A, CDKN2A and NFI can also affect diagnosis and treatment results [79].     
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Table 1: Characteristic mutations in epithelial ovarian carcinoma subtypes. 
Carcinoma 
Subtype 
Potential 
cellular origin 
Gene Activation Gene Inactivation 
HGSC 
Mostly fallopian 
tube epithelium. 
Also ovarian 
surface 
epithelium 
No frequent mutations 
BRCA1, BRCA2: tumor 
suppressor genes that 
help repair DNA 
damage or destroy cells 
if DNA cannot be 
repaired 
TP53: a tumor 
suppressor commonly 
mutated in cancers and 
crucial for genomic 
stability and DNA 
repair 
LGSC 
Serous border 
line tumors 
BRAF: an oncogene 
involved with intracellular 
signaling involved with 
directing cell growth 
KRAS: an oncogene that 
recruits and activates 
proteins necessary for 
tumor growth 
Unknown 
EC Endometriosis 
KRAS 
CTNNB1: operates as a 
signal transducer to 
regulate gene transcription 
and cell–cell adhesion 
PIK3CA: promotes cell 
survival, growth, and 
migration 
PPP2R1A: regulates 
signaling pathways that 
inhibit cell growth and 
division 
BRCA1, BRCA2 
ARID1A: regulates 
gene by altering the 
accessibility of 
transcription factors to 
DNA 
PTEN: a tumor 
suppressor that inhibits 
cellular growth. This 
gene is often mutated 
in cancer 
 
CCC 
Endometriosis/ 
Uncertain 
KRAS 
PIK3CA 
PPP2R1A 
TP53 
PTEN 
ARID1A 
MC Unknown 
BRAF, KRAS 
ERBB2: a receptor tyrosine 
kinase that can interact 
with signaling molecules 
to promote tumor growth 
and block cell death. It is 
commonly amplified or 
overexpressed in cancers 
TP53, CDKN2A:  
a tumor suppressor that 
induces cell cycle 
arrest 
RNF43: a tumor 
suppressor that inhibits 
WNT signaling 
pathway 
Adapted from [6]. 
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II. MICRORNAs 
MicroRNAs (miRNAs) are small noncoding RNAs expressed endogenously in 
eukaryotes and are important elements in post-transcriptional regulation of gene expression 
[80-83]. In 1993, the first microRNA, lin-4, was identified in C. elegans in pioneer papers by 
the Ambros and Ruvkun groups [84, 85]. Despite the importance of lin-4 for the control of 
larvae development timing, it did not encode for a protein. However, it suppressed the 
expression of lin-14 by the interaction between the lin-4 and the 3’UTR of lin-14. It was 
believed for several years that this RNA-RNA interaction is an exclusive phenomenon to 
nematodes development and to lin-4. In 2000, another newly discovered microRNA, let-7, in 
C. elegans was reported to be able to target the 3′UTR of several mRNAs. In addition, the 
3′UTR of one mRNA can harbour many target sites for several microRNAs [86]. The presence 
of miRNA in several cell types among the eukaryotes was then revealed through intense cloning 
effort. These findings suggest a more spread role of miRNAs in regulating gene expressions 
than what was thought previously [80]. In March, 2018, the miRNA database (miRBase) has 
listed ~ 1900 annotated and predicted miRNAs in the human genome. The function of many of 
these miRNAs is still unknown; however, it is now well accepted that miRNAs are involved in 
regulating many biological processes, such as cell proliferation, apoptosis, differentiation, and 
development [87]. In addition, the use of miRNAs as potential diagnostic and therapeutic 
molecules has been suggested [88, 89]. 
 
II. 1. Biogenesis and miRISC Assembly  
miRNAs can generally be classified as “intragenic” or “intergenic” depending on 
their genomic location. Almost half of all annotated miRNAs in humans are located within 
host genes, mainly within the introns of protein-coding genes or other non-coding RNA genes 
[90]. The biogenesis process of miRNAs is relatively consistent. Expression of intronic 
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miRNAs are usually coupled with their host gene, while the transcription of intergenic miRNAs 
is directed by their own promoters. However, it was shown recently that the expression of some 
miRNAs are decoupled from their host genes through independent transcription mechanisms 
and alternative splicing [91]. 
The 18–22 nucleotide (nt) mature miRNA molecules are initially transcribed by RNA 
polymerase II into primary miRNA (pri-miRNA) transcript, containing a 5′ m7G cap and a 3′ 
poly-A tail [92, 93]. Subsequently, pri-miRNAs go through extensive processing within the 
nucleus. The primary maturation step changes pri-miRNA into ~70 nt hairpin miRNA 
precursors (pre-miRNAs). Pri-miRNA cleavage is facilitated by the microprocessor complex, 
which consists of an RNase III endonuclease, DROSHA, and the double-stranded-RNA-
binding protein, DGCR8 (DiGeorge syndrome Critical Region 8) [81, 94-96]. The pre-miRNA 
is then exported to the cytoplasm via a member of the nuclear transport receptor family 
Exportin 5 (XPO5) [94, 97, 98].  
In the cytoplasm, the pre-miRNAs are further processed into mature miRNAs by a 
different RNase III endonuclease, Dicer, [81, 94, 99]. Specifically, Dicer slices pre-miRNA 
near the terminal loop freeing a short, ~ 22 nt, RNA duplex [99-101] (Figure 1.2). Lastly, the 
fully processed mature miRNA molecules are integrated into the miRNA-induced silencing 
complex (miRISC) [102, 103]. 
 The core element of miRISC is a member of the Argonaute (AGO) protein family that 
binds miRNA. AGO family proteins comprise four members in humans (AGO1-4). The 
miRISC loading complex facilitates miRNA loading into AGO, where the 5′ or 3′ ends of the 
miRNAs are clamped to different domains of AGO [81, 104]. miRNA loading involves ATP-
dependent loading of the miRNA duplex into AGO and its subsequent unwinding [105].  
miRNA duplex consists of a “guide strand” and a “passenger strand”. The guide 
strand will serve in target transcript recognition, while the passenger strand will be ejected 
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from the AGO protein. However, the criteria of strand selection remain unclear [106]. Some 
studies, however, suggested that the more thermodynamically stable 5′ end of the miRNA will 
be ejected through miRISC maturation, while the strand with less stable 5′ end will be anchored 
to AGO. The AGO is then interacting with the strategically positioned phosphate backbone of 
the guide strand, while the 5′ and 3′ ends are anchored exposing the “seed-region” (nucleotides 
2-8, from the 5′ end) where miRNA-loaded miRISC recognizes the 3′ UTR of target mRNAs 
[107-110].  
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Figure 1.2. MicroRNA biogenesis and RNA-induced gene silencing. Transcription of 
primary micro RNA (Pri-miRNA), that contain a double-stranded stem, a loop, ssRNA tails, 
a 5ʹ cap and 3ʹ poly-A tail, from miRNA genes is followed by cleavage to precursor mRNA 
(Pre-miRNA) by the Drosha nuclear RNase III and DGCR8. The Pre-miRNA is then exported 
to the cytoplasm by Exportin 5 via nuclear pores. In the cytoplasm, Pre-miRNA is further 
processed by RNase activity of Dicer and TRBP to the mature microRNA duplex. The duplex 
loads onto Argonaut ribonucleases in the miRISC complex and separates. One of the mature 
miRNA strands (red strand) mediates small interfering RNA silencing by degrading the target 
mRNA or interfering with translation. The outcome of miRISC formation varies with the 
degree of complementarity of the seed sequence of miRNA and 3′ untranslated regions (UTR) 
of the target mRNA. AGO2 loaded miRNA can lead to endonucleolytic cleavage of the 
recognized target or translational repression and deadenylation. Reprinted with permission 
from [111]. 
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II. 2. MiRNA Nomenclature 
The newest report from miRBase, Release 22: March 2018, shows 38589 identified 
miRNAs across different species, albeit the function of many of these miRNAs remains to be 
explored and validated [112-114]. miRNA nomenclature has changed over time as well, as our 
understanding of miRNA biogenesis and mechanism. The genes discovered in early genetic 
studies were named following their phenotypes (for instance, lin-4, let-7 and lsy-6), whereas 
the majority of miRNAs discovered from cloning or sequencing were given numerical names 
(for instance, the lin-4 homologues in other species are known as mir-125). Pre-miRNA 
hairpins are referred to as “mir”, while the mature miRNAs are referred to as “miR”. Genes 
encoding miRNA species are marked with lettered suffixes (for instance, mir-125a and mir-
125b). To differentiate mature miRNA species transcribed from different genomic loci with 
100% sequence identity, numeric suffixes are inserted after the names of the miRNA (for 
instance, mir-125b-1 and mir-125b-2). Each miRNA’s name begins with a prefix indicating the 
species of origin. 
 Initially, one strand of miRNA duplex was believed to be the main strand, while the 
other one was believed to be non-functional and subject to degradation. The later-degraded 
strand was denoted with a “*”. Further investigation showed that the majority of the “*” strands 
are fully functional and may have similar rates of maturation to that of the guide strands, as 
well as exert a unique biological function [115, 116]. While a locus may contain a cluster of 
multiple miRNAs, every pre-miRNA generates two mature miRNAs: one from the 3′ strand 
and one from the 5′ strand of the precursor. Currently, the old “*” naming system is seized and 
replaced with the modern system -3p and -5p, which processed from the 3′ and 5′ arm 
respectively. For instance, the precursor hairpin of miRNA 590 would be mir-590, and the two 
arms of the mature miRNA would be miR-590-3p and miR-590-5p [116].  
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II. 3. Mechanism of miRNA-Mediated Gene Regulation  
Despite the lack of a unified model, several mechanisms have been proposed to describe 
the miRNA action. Generally, the repressive effect of miRNAs is exerted by either mRNA 
cleavage, mRNA decay, or repressing translation [117] (Figure 1.2). It is widely believed that 
miRNAs bind to a specific sequence at the 3′ UTR of their selected mRNA, which induces 
mRNA deadenylation and decapping as well as translational repression [118]. More recently, 
it has been shown that miRNAs can also have binding sites on other regions of the mRNA 
including, coding sequence and 5′ UTR, or to DNA promoter regions [119]. Interestingly, it 
was found that when miRNA interacts with the promoter region, it can induce transcription, 
while binding to the coding region or the 5′ UTR represses gene expression and exerts silencing 
effects [120-122]. 
miRNA guide strand and AGO are the minimally required components to form miRISC 
[123]. The loaded miRNA gives miRISC its target specificity via complementary 
miRNA:mRNA interactions.  The region of target interaction is termed the miRNA response 
element (MRE). Depending on the degree of the complementarity between miRISC and MRE, 
one of two routes can be taken, 1- AGO2-dependent splicing can cleave fully complementary 
target mRNAs or 2- miRISC-mediated translational initiation inhibition and target mRNA 
deadenylation and decay [124]. A perfect complementary between miRNA and MRE will 
induce the endonuclease activity of AGO2 and leads to mRNA cleavage [124]. Nonetheless, 
this perfect matching disrupts the interaction between AGO and 3′ end of the miRNA 
promoting its degradation [125]. Although the target mRNA cleavage is the main mechanism 
found in plant miRNAs and siRNAs, it is infrequently observed in miRNA:mRNA interactions 
in human [111]. In mammalian cells, the majority of miRNA-MRE interactions possess a 
central or 3′ mismatch. This imperfect coupling prevents AGO2 endonuclease activity allowing 
a mediating role for AGO2 in RNA interference [126]. Albeit all four AGO proteins in humans 
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interact with miRNAs, only AGO2 has endonucleolytic activity [127].  
The second gene silencing mechanism mediated by miRNA is via suppression of 
translation initiation and/or degradation of target mRNA. This process is mediated through the 
interaction between AGO and GW182, which is an essential member of a protein family 
regulating the downstream repression stages [107]. In addition to binding to AGO, GW182 can 
bind to the poly-A binding proteins on the mRNA poly-A tail. Also, it is capable of interacting 
with cellular deadenylases like the CCR4/NOT complex to promote deadenylation and 
indirectly mRNA decapping, which results in target mRNA instability and degradation [128]. 
The last mechanism is through repression of translation. However, it is still unclear how exactly 
miRNA mediates it. However, some evidence refers to the miRNA’s ability to interfere with 
the translation initiation process  [129]. This translation repression was initially observed in the 
lin-4 mediating lin-14 protein level without affecting the mRNA levels [85]. 
 
II. 4. Dysregulation of miRNA Expression in Cancer 
Studies have shown that 30-60% of human protein-coding genes are regulated by 
miRNAs [130]. miRNAs are reported to modulate many biological processes including: 
differentiation, cell cycle, apoptosis, proliferation, and immune reaction [87]. In cancer, 
miRNA expression dysregulation was attributed to both genetic and epigenetic factors and 
mechanisms. Those factors may include one of the following: 1- alteration of miRNA genes by 
amplification or deletion. 2- histone acetylation and methylation at the miRNA promoter and 
epigenetic modifications, or 3- abnormalities in miRNA biogenesis and defects in 
transcriptional control machinery (Figure 1.3). 
In chronic lymphocytic leukemia, chromosomal region (13q14) is frequently deleted. 
This region was shown to encode for miR-15 and miR-16 that target the anti-apoptotic factor 
B cell lymphoma 2 (BCL2). Both miRNAs showed expression alteration in cancer cases [131]. 
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In addition, another study in ovarian cancer demonstrated the association between mutations at 
genomic loci containing miRNA genes and cancer. The study showed that many miRNA loci 
at chromosomal fragile sites, and almost half of these miRNA located in a frequently 
translocated region in cancer cases [132, 133]. 
During cancer, gene duplication and/or abnormal methylation of the miRNA promoter 
can induce transcription of pri-miRNA [134]. DNA hypo- or hyper-methylation and histone 
hypo- or hyper-acetylation at the promoter of miRNAs was reported to alter miRNA genes 
[134, 135]. On the other hand, acetylation of histone H3 lysine 9 or 14 (H3K9ac and H3K14ac) 
and tri-methylation of histone H3 lysine 4 (H3K4me3) are reported to affect miRNA gene 
promoters [136, 137]. 
Abnormalities in miRNA biogenesis and defects in transcriptional machinery were also 
associated with cancer progression [138-140]. In the mouse germ line, deletion of Dicer1 leads 
to early embryonic fatality around embryonic day 7.5 [141], and Dicer1-knockout in 
embryonic stem cells significantly affected cell differentiation and proliferation [142, 143], 
while partial deletion of Dicer1 or Drosha induced tumorigenesis phenotypes [144]. In 
addition, mutation in Exportin 5 (XPO5) prevented the exportation of miRNA from the nucleus 
and resulted in carcinoma progression [145]. 
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Figure 1.3. microRNA (miRNA) biogenesis dysregulation during cancer initiation and 
progression [146]. 
 
 
 
 
 
 
 
 
 
 
 
22 
 
II. 5. MicroRNA-590 (miR-590) 
MicroRNA-590-3p (miR-590-3p) is located on chromosome 7q11.23 (Figure 1.4) and 
is contained within an intron of the eukaryotic translation initiation factor 4H (eIF4H) gene. 
eIF4H has been shown to stimulate translation in rabbit reticulocytes [147]. It has also been 
reported that eIF4H was overexpressed in most human ovarian cancer tissues [148], suggesting 
a critical role for eIF4H in carcinogenesis. miR-590 is expressed in heart, breast, nerves, 
stomach, and ovaries. In addition, it plays a significant function in cell differentiation, 
proliferation, and tumor regulation, indicating that miR-590 is engaged in several physiological 
processes. In a recent study, miR-590-3p was shown to promote cardiomyocyte proliferation 
and induce cardiac regeneration after myocardial infarction [149]. These findings are in 
accordance with other previous studies where miR-590-3p promoted ovarian cancer [150], 
lymphoblastic leukaemia [151], colorectal [152],  glioblastoma [153] and colon cancer [154]. 
Both the mature miR-590-3p and mir-590-5p (Figure 1.5) were reported to have an independent 
function from each other, and can be associated with both promoting and inhibiting cancers 
[151, 152, 154-156]. This dual function of miR-590 would likely be attributed to differential 
mRNA target sets between the 5p and 3p strands and will be further discussed in (chapter 2). 
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Figure 1.4. Gene location of miR-590. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5.  Sequences of miR-590-3p and miR-590-5p 
 
 
 
 
 
 
 
 
has-miR-590-5p  
16 – gagcuuauucauaaaagugcag - 37  
has-miR-590-3p  
56 – uaauuuuauguauaagcuagu- 76  
 
24 
 
III. THE FORKHEAD BOX (FOX) SUPERFAMILY 
The Forkhead box (FOX) proteins are transcription factors that play critical roles in 
several processes. The FOX gene family encodes for proteins which control the transcription 
of genes taking part in functions such as proliferation, organ development or regulating 
metabolic homeostasis [157]. The FOX superfamily comprises 50 FOX genes in the human 
genome and 44 in the mouse, and are divided into 19 subfamilies (Table 2) [158]. Depending 
on the family member and cell type, FOX genes are differentially expressed in various cancers. 
However, they can play either a tumor suppressing or a tumor promoting role and gene 
expression can be regulated during transcription or translation.  
Forkhead (fkh) was the first FOX gene discovered in Drosophila [159], followed by 
FOXA1 identification and characterized in rats [160]. In 1990, some protein groups were found 
to share a similar DNA-binding domain, later called the Forkhead domain (FHD), which was 
found to be highly conserved among the entire FOX family [161].  In 1993, the crystal structure 
of the DNA-bound Forkhead domain was solved for FOXA1 [162]. Many other FOX structures 
followed, including the DNA-binding domains of FOXM1, FOXO1, FOXO3, FOXO4, FOXP1, 
FOXP2, FOXK1, and FOXK2 [162].  
 
Unified naming system 
Prior to 2000, FOX genes lacked an integrated naming convention and were named by 
the investigators who found them. This old naming system was used until the Winged 
helix/Forkhead nomenclature committee implemented a unified nomenclature system for the 
FOX family members. This system described the FOX family as the set of genes that have 
sequence homology to the canonical Winged helix/Forkhead DNA-binding domain. In 
addition, subclasses FOXA and FOXO were defined according to a phylogenetic study of the 
Forkhead domain  [163].  
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Table 1.2: List of the FOX genes in humans and mice, chromosomal locations and percentage 
sequence similarity between the human and mouse orthologous proteins. 
Adapted from [158] 
Human Mouse 
% Similarity 
Protein Chromosome Orthologue Chromosome 
FOXA1 14q12-q13 FOXA1A 12 96.2 
FOXA2 20p11 FOXA2 2 97.4 
FOXA3 19q13.2-q13.4 FOXA3 7 90.4 
FOXB1 15q22 FOXB1 9 99.7 
FOXB2 9q21.2 FOXB2 19 92.6 
FOXC1 6p25 FOXC1 13 95.1 
FOXC2 16q24.1 FOXC2 8 92.6 
FOXD1 5q12-q13 FOXD1 13 85.8 
FOXD2 1p34-p32 FOXD2 4 94.3 
FOXD3 1p31.3 FOXD3 4 90.8 
FOXD4 9p24.3    
FOXD4L1 2q14.1 FOXD4 19 63.7 
FOXD4L2 9p12    
FOXD4L3 9q13    
FOXD4L4 9q13    
FOXD4L5 9q13    
FOXD4L6 9q12    
FOXE1 9q22 FOXE1 4 91.2 
FOXE3 1p32 FOXE3 4 79.3 
FOXF1 16q24 FOXF1 8 97.4 
FOXF2 6p25.3 FOXF2 13 94.6 
FOXG1 14q11-q13 FOXG1 12 96.3 
FOXH1 8q24 FOXH1 15 76.3 
FOXI1 5q34 FOXI1 11 89.9 
FOXI2 10q26.2 FOXI2 7 78.6 
FOXI3 2p11.2 FOXI3 6 84.5 
FOXJ1 17q25.1 FOXJ1 11 94.5 
FOXJ2 12p13.31 FOXJ2 6 93.2 
FOXJ3 1p34.2 FOXJ3 4 96.5 
FOXK1 7p22 FOXK1 5 92 
FOXK2 17q25 FOXK2 11 95 
FOXL1 16q24 FOXL1 8 73 
FOXL2 3q23 FOXL2 9 96.8 
FOXM1 12p13 FOXM1 6 88.6 
FOXN1 17q11-q12 FOXN1 11 90.9 
FOXN2 2p22-p16 FOXN2 17 48 
FOXN3 14q24.3-q31 FOXN3 12 90 
FOXN4 12q24.12 FOXN4 5 86.2 
FOXO1 13q14.1 FOXO1 3 95.4 
FOXO3 6q21 FOXO3 10 96.1 
FOXO4 Xq13.1 FOXO4 X 93.3 
FOXO6 1p34.2 FOXO6 4 86 
FOXP1 3p14.1 FOXP1 6 94.6 
FOXP2 7q31 FOXP2 6 99.7 
FOXP3 Xp11.23 FOXP3 X 91.4 
FOXP4 6p21.1 FOXP4 17 80.5 
FOXQ1 6p25 FOXQ1 13 93.6 
FOXR1 11q23.3 FOXR1 9 77.7 
FOXR2 Xp11 FOXR2 X 73 
FOXS1 20q11.1-q11.2 FOXS1 2 83.3 
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III. 1. FOXA Subfamily 
Forkhead box A2 (FOXA2) is a transcription factor involved in embryonic 
development, metabolism and homeostasis [164]. It was formerly known as hepatocyte nuclear 
factor 3β (HNF3β) due to its function in regulating specific gene expression patterns in the 
liver [160].  The FOXA2 gene is located on chromosome 20p11.21, and the translated protein 
can bind to the DNA consensus sequence 5-[AC]A[AT]T[AG]TT[GT][AG][CT]T[CT]-3 
[162]. This gene participates in cell signal transduction, inhibition or activation of the 
transcriptional activity of target genes [165], and controls metabolism [166]. In addition, it 
plays an important role in the development [167] and maturity of organs and tissues [168]. 
It was believed that FOXA1 and FOXA2 have some functional redundancy. Although a 
recent study showed that FOXA2 is involved in tumor development, FOXA2 role as a tumor-
suppressor has been also reported in lung cancer [169, 170], pancreatic cancer [171], as well 
as in gastric tumors [172]. Interestingly, FOXA2 has been reported as both a tumor promoter 
and tumor suppressor in breast cancer [200, 201]. On the other hand, in liver cancer, the 
function of FOXA2 development is sexually dimorphic, as it has a tumor-promoting function 
in males and tumor-suppressing function in females [173]. 
  
III. 2. Structure of FOXA2 
The FOXA2 gene is ~ 2400 bp in length and is located in chromosome 20p11.21. As a 
FOXA family member, FOXA2 has a Forkhead domain that can form a complex to target DNA 
motifs [162]. Recently, FOXA was identified as a pioneer factor, regulating chromatin 
accessibility to other factors, and also binds to enhancers and promoters [164, 174, 175]. In 
addition, FOXA2 is the only FOX member that has an AKT2/PKB phosphorylation site at the 
N terminus of the FHD which suggests additional unique regulatory function [164]. 
Structurally, FOXA2 also contains two nuclear localization sequences (NLS) that flank the 
FHD [176, 177] (Figure 1.6). 
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Figure 1.6: Structure of Forkhead box protein A2 protein. FOXA2 has two nuclear 
localization sequences and two transactivation domains. FOXA2 possesses a winged helix, 
which located in the center of FOXA2, two Transcription Activation Domain (TAD), one at 
each end. NLS refers to nuclear localization sequences. Reprinted (with modifications) 
from  [178]. 
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III. 3. FOXs in Diseases 
Given their primary function in the expression of numerous genes that influence cell 
survival and proliferation, it was suggested that FOX family members may play a role as cancer 
therapeutic targets. FOX family members were reported to have either up- or down-regulating 
effects in several cancer types. FOXP1 has been shown to act as an oncogene and/or as an anti-
oncogene, based on the cell type, even though these observations are principally dependent on 
correlations between mRNA levels and clinical results [179]. Likewise, FOXM1 is considered 
an oncogene that is widely expressed in several carcinomas and expressed at lower levels in 
normal cells [180]. 
Breast and prostate cancers are the two major cancers that are influenced by hormones. 
It has been reported that FOXA1/2 play a crucial role in the regulation of estrogen-receptor-
alpha positive (ERα) and androgen receptor (AR) [181-183], and the expression of FOXA in 
ERα-positive breast cancers and AR-positive prostate cancers were observed [183, 184]. 
Metastasis is responsible for ~ 90% of cancer deaths [6]. The epithelial–mesenchymal 
transition (EMT) is considered an important requirement for metastasis in most carcinomas, 
allowing cancer cells to disassociate from the primary tumor by enhancing cell motility, 
invasion, and cell adhesion molecule profiles, such as E-cadherin [185]. FOXA2 was reported 
to strongly inhibit metastasis while decreased expression levels promoted cancer progression 
in lung cancer [169, 170]. In addition, FOXA2 was reported to regulate epithelial marker, E-
cadherin, expression [186].  This indicates its role in EMT regulation, and its importance in 
suppressing tumor metastasis via EMT down-regulation.  
Moreover, FOXA1/2 were reported to be essential for sexual dimorphism in liver 
cancer. In FOXA1/2 mutant mice, it was shown that tumors’ sizes were increased in females, 
while decreased in males. This dimorphism effect was essentially achieved through the 
recruitment of ERα and androgen receptor (AR) to their relevant targets in the liver [173].   
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IV. VERSICAN 
Versican (VCAN) is a large chondroitin sulfate proteoglycan that provides a loose 
hydrated matrix during key events in development and disease [187]. VCAN is one of the main 
components of the extracellular matrix (ECM). Besides providing necessary support for the 
physical shape of the cell and its behaviour, ECM is a key element in cell adhesion, 
proliferation, migration and differentiation [188]. ECM remodelling takes place through 1- 
signal transduction, which in turn results in behavioural changes in cell motility and 
proliferation, and 2- through the expression of proteins that control the dynamic process of 
ECM composition and decomposition in tissues [189]. 
VCAN is comprised of 15 exons located within chromosome 5 (5q14.2-q14.3), and is 
encoded by the VCAN gene. It has a molecular mass of ~500 kDa, and it was first detected in 
human’s healthy and cancerous brain tissue [190].  
VCAN has a glycosaminoglycan-domain (GAG domain), a globular G1-domain at its 
N-terminal, and a globular G3-domain at the C-terminal. All isoforms have these G1 and G3 
globular domains [191]. Alternate splicing of the GAG-domain leads to four different isoforms 
of VCAN; namely, V0, V1, V2, V3 many of which have been discovered in a variety of tissues 
[192-194] (Figure 1.7). V0 has a GAG-α exon and a GAG-β exon. V1 has a GAG-β exon. V2 
has the GAG-α exon. V3 contains only the two globular domains, G1 and G3.  As a result, this 
latter isoform exists as a glycoprotein and not as a proteoglycan [195]. The size difference of 
chondroitin sulphate attachment regions in between the isoforms may lead to functional and 
structural diversity. 
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Figure 1.7: Structure of different versican isoforms. Alternative splicing of the mRNA 
transcript leads to the formation of four different versican isoforms, V0, V1, V2 and V3. All 
isoforms interact with hyaluronan. Reprinted with permission from  [196] 
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IV. 1. The Role of Versican Isoforms in Normal and Cancer Tissues 
The function of each VCAN isoform in normal and cancer tissues is still unclear [197]. 
During late embryonic developmental stages, V0 and V1 isoforms are expressed prominently; 
however, V0 isoform expression diminishes in adult tissues. To date, it has not been 
demonstrated that the most common isoforms, V0 and V1, can play different roles [198] but 
studies showed that V1 promotes cell proliferation and can protect fibroblasts from apoptosis 
[199]. In contrast, isoform V2 was shown to inhibit cell proliferation and does not appear to be 
involved in apoptosis resistance [199]. Interestingly, some studies have suggested that the 
smallest VCAN variant, V3, which contains only G1 and G3-domains may have a different 
role and properties from the other isoforms [200]. V3 was reported to be expressed in growth 
factors or cytokines activated endothelial cell cultures; however, the exact function of V3 in 
activated endothelium is yet to be identified. On the other hand, V3 overexpression in smooth 
muscle cells of the artery increased their adhesion to cell culture plates but inhibited cell 
proliferation and migration in wound-healing assays [200]. Also, although V3 overexpression 
significantly decreased melanoma cancer cells’ growth in vivo and in vitro, it promoted cells 
metastasis into the lung, suggesting a dual role of V3 in cancer development and progression 
[201, 202]. 
Many other studies have confirmed elevated expression levels of VCAN in several 
cancers such as brain tumors, melanomas, osteosarcomas, lymphomas, as well as breast, 
prostate, colon, lung, pancreatic, and ovarian endometrial cancers [203-210]. In general, higher 
VCAN level was correlated with poor outcomes and cancer recurrence in prostate, breast and 
many other cancer types [198]. In ovarian cancer, serous epithelial cancers were correlated with 
high stromal VCAN level and this was linked to a reduction in survival rates. On the other 
hand, early stage clear cell carcinoma was associated with high VCAN levels which promoted 
recurrence-free survival. In normal ovaries, however, VCAN expression is precisely regulated 
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[211]. Researchers have shown that different mechanisms are accountable for differentially 
controlling localization, protein expression, and for the biological role of VCAN [212]. For 
example, VCAN level is induced in the ovary as a result of the natural wound-healing [213], 
follicle growth [211], and inflammation [214] events that follow the release of the ovum. 
Although it has been reported that the VCAN level is positively correlated with patient’s poor 
outcome, VCAN level cannot be used as a prognostic marker for EOC progression [215]. 
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V. CYCLIN G2 
Cyclins are an important family of cell cycle regulators [216]. They achieve their 
function via activation of specific cyclin-dependent kinases in order to promote cell cycle 
progression [217-219]. One of these cell cycle controllers is Cyclin G2, a protein encoded by 
the CCNG2 gene in humans [220, 221]. Although the function of CCNG2 is not completely 
understood, a recent study suggested that it has an important role as a tumor suppressor [216]. 
It has also been reported that the level of CCNG2 is inversely correlated with the progression 
of breast cancer [223], acute leukaemia [224], oral [225], thyroid [226], as well as gastric 
cancers [224, 227].  Our lab has previously shown that CCNG2 modulated Nodal-regulated 
anti-proliferative effect in EOC cells, and that Cyclin G2 is highly unstable [228, 229]. In 
addition, we recently showed that overexpression of CCNG2 significantly suppresses cell 
proliferation, migration and invasion both in vitro and in vivo [216].  
The G-type cyclin members, including, cyclin G1, cyclin G2 and cyclin I, possess a 
relatively similar sequence homology and functional resemblance [220, 230]. While cyclin G2 
has a high sequence identity with various G-types cyclins (41% homology to cyclin I and 71% 
homology to cyclin G1) [231], there are some differences in their promoter sequence, 
regulation, and expression, indicating a non-compensatory physiological function [220, 232].  
 
V. 1. Structure and Expression Profile of Cyclin G2 
The protein structure of cyclin G2 is classified into three main domains: the amino-
terminal domain, the carboxyl-terminal domain, and a cyclin box of nearly a 110 amino acids 
[221]. Both cyclin A and cyclin G2 have a similar cyclin box, which interacts with CDK-2 to 
regulate cell transition from one phase to the next [233]. However, the means by which CDK-
2 binds to any cyclin-dependent kinase partner is still unknown [231, 234]. As a result, cyclin 
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G2-association with other regulatory members of the cell cycle may be possible. However, this 
association probably does not occur through the cyclin box domain [234]. 
Cyclin G2 is conserved in primates and other species [235], and it has been reported to 
have an inverse correlation between cyclin G2 expression with age in some species [235]. 
Monitoring cyclin G2 levels in the mice liver over time showed that protein levels vary from 
3-6 weeks of age. When the tissue ages and becomes mitotically silent, cyclin G2 levels 
decrease more than two-fold when compared with younger tissues [235].  
 
V. 2. Functions of Cyclin G2 
Cyclin G2 is an unconventional cyclin which does not follow the behaviour of the other 
cyclin family members [232]. High levels of cyclin G2 are correlated with cell cycle quiescence 
in several cell types [225, 231, 232, 234]. Its expression fluctuates greatly during the cell cycle. 
In response to DNA damage and growth inhibitory signals, it has been observed that cyclin G2 
protein level is consistently up-regulated [225, 230, 231, 234]. In addition, cyclin G2 
expression was greatly reduced during proliferation, while it is mainly expressed during cell 
cycle arrest and during the G0 phase [230, 234].  
 In the tightly regulated process of the cell cycle, the progression of cell differentiation 
was also associated with cyclin G2 expression, as its level is often the highest in terminally 
differentiated tissue [236]. Moreover, cyclin G2 overexpression following implantation 
induces uterine stromal cells differentiation [237].  
 
V. 3 Cyclin G2 Dysregulation in Cancer 
Malignancy progression is highly influenced by many other cellular processes, 
including DNA damage, cell differentiation, and indeed cell cycle control. Thus, it is suggested 
that cyclin G2 association with its protein targets regulates its tumor suppressing effect. On the 
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other hand, when the oncogenic signaling pathways result in a reduction of cyclin G2 
expression level, its ability to associate or bind to its partners is also affected, and this leads to 
the progression of diseases [238-240]. 
Studies have shown that several oncogenic signaling pathways can result in the 
reduction of cyclin G2 expression, while some growth-inhibitory signals are able to upregulate 
its expression. Furthermore, cyclin G2 expression is induced by several anticancer drugs [238-
240]. Interestingly, many studies showed that cyclin G2 overexpression inhibits cell 
proliferation in human cell lines [225, 232, 241] and inhibits colony and spheroid formation as 
well as tumor formation in vivo. Cyclin G2 was also found to positively associate with survival, 
but to negatively correlate with cancer progression [216]. 
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VI. WNT/β-CATENIN SIGNALING 
The Wnt signaling pathway is a crucial pathway that regulates cell survival, 
proliferation, polarity, and the fate of stem cells in both embryonic and adult tissues [242]. The 
Wnt pathway is characterized into β-catenin dependent (canonical), which will be the focus of 
this review, and β-catenin independent (non-canonical) signaling pathways. While components 
of non-canonical Wnt signaling have not been well-characterized, multiple elements of 
canonical Wnt signaling (Wnt/β-catenin) have been identified. 
One of the important dynamic proteins regulating the canonical Wnt pathway is β-
catenin. β-catenin is located in several subcellular compartments within the cytoplasm, or 
within the junctions where it plays a role in the cell-cell contact stabilization. In addition, β-
catenin may also be located within the nucleus where it stimulates the expression of target 
genes by binding to transcription factors (Figure 1.8) [243]. Disruption of the Wnt/β-catenin 
pathway or mutations in β-catenin is associated with many different diseases including cancer 
[243, 244]. 
Wnt signaling involves in the regulation of target genes associated with cell cycle 
progression [245, 246], reduction of cell-cell contact [247], and EMT genes [248]. Canonical 
Wnt signaling cascades are activated by the binding of extracellular Wnt ligands to its 
receptors. Wnt ligands family comprises 19 glycoprotein members [249]. Upon production, 
Wnts are readily secreted by signaling cells [250, 251]. Once they reach the membrane of a 
target cell, Wnt ligands bind to the membrane receptors Frizzled (Fz) [252]. Lipoprotein 
receptor-related protein (LRP) 5 or 6 are another important trans-membrane receptor [253, 
254]), which interacts with Fz to form a Wnt receptor complex and initiate Wnt signaling 
[255]. The cytosolic β-catenin level is highly regulated by the β-catenin destruction complex. 
The destruction complex is composed of tumor suppressor proteins Axin, Adenomatous 
polyposis coli (APC), glycogen synthase kinase 3 (GSK3) and casein kinase I (CKI), Protein 
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phosphatase 2 (PP2A) and β-transduction repeat-containing protein (β-TrCP) [256].  
Axin acts as a scaffold protein that binds to and brings CKI, GSK3, and β-catenin 
into close proximity. This binding promotes phosphorylation and subsequent inhibition of β-
catenin activity [257, 258]. In the presence of Wnt signaling, LRP is phosphorylated by CKI 
and GSK3, inducing the translocation of the β-catenin destruction complex closer to the 
membrane [259] and increasing the binding between GSK3 and LRP.  Dishevelled (Dvl) 
molecule is then interacts with LRP leading to the activation of DVL and inactivation of 
GSK3β, which leads to the dissociation of Axin and GSK3. The GSK3 plasma membrane-
associated pool is essential to activate signaling by phosphorylation of CKI and LRP, while the 
GSK3 destruction complex associated pool phosphorylates CKI and β-catenin to inhibit 
signaling. Consequently, the disruption of the destruction complex prevents β-catenin 
phosphorylation and degradation subsequently. The stability of β-catenin by Wnt signaling 
results in the translocation of β-catenin to the nucleus and activation of Wnt target genes 
through interactions with TCF/Lef transcription factors; however, β-catenin cannot bind DNA 
directly and serves as a co-activator [260] 
 
VI. 1. TCF/Lef Transcription Factor Family 
In the absence of Wnt signaling, TCF/Lef possess limited transcriptional activity due 
to their interaction with Groucho transcriptional repressors [261, 262]. As β-catenin enters the 
nucleus, it displaces Groucho, forming a transcriptionally active complex with TCF and other 
co-activators [263]. TCF/ β-catenin transcriptional activity is modulated through a variety of 
signals: (i) TCF/Lef isoforms lacking the β-catenin binding domain can antagonize TCF/ β-
catenin complex activity [264, 265], (ii) expression of nuclear antagonists, Chibby and ICAT,  
which can bind to β-catenin to limits its interaction with transcription factors and co-activators, 
promoting its nuclear exclusion [266, 267], and (iii) post-translational modifications such as 
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phosphorylation and acetylation that can lead to activation, repression, or degradation of 
TCF/Lef proteins [264, 265].  
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Figure 1.8: Wnt/ β-catenin signaling pathway. In the absence of Wnt signaling (left), the 
destruction complex phosphorylates β-catenin. β-TrCP then ubiquitinates β-catenin leading to 
its degradation. In the presence of Wnt signaling (right), Wnt binds to its Fz receptor and 
recruits Disheveled (Dvl). Dvl promotes the phosphorylation of LRP5/6 co-receptor through 
CK1 and GSK3β. This leads to a high-affinity binding of Axin and subsequent disruption of 
the destruction complex. When the destruction complex is inactivated, β-catenin is 
accumulated, stabilized and translocated to the nucleus. In the nucleus, β-catenin binds to 
DNA-binding proteins of the T-cell factor (TCF) and lymphoid enhancer-binding factor 1 (Lef-
1) to regulate Wnt target gene transcription. Reprinted with permission from [243]. 
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VI. 2. β-Catenin Protein Characteristics and Its Physiological Functional Roles 
β-catenin is a highly conserved protein [268]. The β-catenin function is strongly 
correlated with the structural components that allow it to form complexes with several proteins. 
The flexible structures of the C- and N- terminals of β-catenin facilitate the interaction with 
transcription factors as well as allows for its phosphorylation. On the other hand, the central 
region acts as a platform that mediates protein-protein interactions [269] (Figure 1.9).  
In addition, β-catenin levels are highly dependent on a delicate balance of 
phosphorylation events through the interaction with members of the destruction complex, Axin, 
APC, CK1 and GSK3β. These phosphorylation events allow β-catenin to be recognized, and 
subsequently ubiquitinated by the β-transduction repeat-containing protein E3 ubiquitin ligase 
β-TrCP and hence, result in its proteasomal degradation [268, 270]. 
 
 
 
 
 
Figure 1.9: The structure of β-catenin. β-catenin consists of a highly conserved  Armadillo 
repeat domain and relatively unstructured N- and C- terminal domains. β-catenin N-terminal 
GSK3β and CKI phosphorylation sites are required for proteasome-mediated destruction by β-
TrCP. The transcriptional activation domains (TAD) are required for nuclear signaling. Within 
the Armadillo repeat domain, many of the β-catenin partners compete for the same binding site. 
Adapted and reprinted with permission from [80]. 
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VI. 3. β-Catenin Dysregulation and Cancer 
Dysregulation of β-catenin signaling can affect many cellular processes such as 
proliferation, survival, and stem-cell biology; all of which are frequently associated with 
malignancy development, progression and transformation [271-273]. Activating mutations in 
β-catenin gene were observed in several types of tumors [274].  In ovarian cancer, as well as 
many other types of cancer, alterations in the levels of protein components within Wnt/β-
catenin pathway have been shown to play a vital role in the tumorigenesis [275]. In 
endometrioid carcinoma, β-catenin nuclear expression is widely observed suggesting that the 
activation of the β-catenin-TCF signaling pathway facilitates the development of this 
carcinoma subtype [276]. Also, the dysregulation of the Wnt signaling components in other 
ovarian cancer subtypes may promote cancer development [216, 277]. Furthermore, recent 
studies have indicated that Wnt/β-catenin pathway promotes ovarian cancer stem cell self-
renewal [279, 280], chemoresistance [281], and metastasis [278].  
In a previous study on EOC cells, we showed that cyclin G2 exerts anti-tumor effects 
by attenuating β-catenin signaling, and enhances the recruitment of the destruction complex 
[216]. CCNG2 was found to downregulate key Wnt components LRP6 and DVL2, leading to 
a decrease in total β-catenin and an increase in phosphorylated β-catenin [216]. This 
regulation leads to β-catenin degradation and suppression of β-catenin/TCF transcriptional 
complex activity as the consequence. With high level of CCNG2 and low level of β-catenin 
in the cytoplasm, the accumulation of β-catenin in the nucleus will be limited and signal 
transduction will be inhibited. In contrast, inhibition of CCNG2 expression results in 
accumulation of β-catenin in the nucleus, thus inducing TCF/Lef signaling to activate the 
transcription of its target genes and affecting cell-cell adhesion [282]. In fact, β-catenin 
accumulation in the nucleus can be considered a marker for metastasis progression [283-287]. 
This is likely attributed to the transcriptional activation of mesenchymal genes that results in 
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epithelial-to-mesenchymal transition (EMT), a hallmark of cancer initiation and development 
[288]. Given its important regulatory role in regulating pathways, β-catenin has become an 
important target of many potential therapeutic treatments [289]. 
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VII. RATIONALE, HYPOTHESIS, AND OBJECTIVES 
Ovarian cancer is the deadliest of the gynecologic malignancies, and is the fifth leading 
cause of cancer-related death among women [5]. In part, this is due to absence of effective 
early screening methods for EOC when the disease is at its early, and more manageable, stage. 
As such, the low survival rate for women with EOC is in part due to the lack of effective 
treatment for the advanced cancer, as well as from our incomplete understanding of how exactly 
EOC develops [290].  
After their discovery in 1993, miRNA research quickly rose in popularity leading to 
~1900 validated miRNAs being identified in the human genome in 2017 [291-293]. miRNAs 
have shown to regulate nearly all physiological and pathological processes. In cancer therapy 
miRNAs have shown great promise as both therapeutic targets and potential biomarkers. 
Therefore, we were interested in studying the effect of miRNAs in regulating ovarian cancer 
and their potential use as early diagnostic markers of EOC. Since we have found that CCNG2 
exerts tumor-suppressing effects in EOC [228], we searched for miRNAs that may target 
CCNG2.  Among the several miRNAs tested, miR-590-3p exhibited the strongest effect on 
promoting cell proliferation. At the beginning of our study, little was known about the function 
of miR-590-3p, with one report about its role in promoting cardiomyocyte proliferation and 
induce cardiac regeneration after myocardial infarction [149], and another report about its role 
in hepatocellular carcinoma [294]. Although the role of miR-590-3p in ovarian cancer was 
unknown, it was identified as one of the dysregulated miRNAs in EOC tumors [295], 
suggesting its potential role in EOC development. 
Based on these findings, we hypothesize that miR-590-3p promotes ovarian cancer 
progression. Thus, the objectives of my Ph.D. study were to determine the function of miR-
590-3p in EOC development and to investigate the mechanisms by which miR-590-3p exerts 
tumorigenic effects on EOC cells. 
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CHAPTER 2 
MICRORNA-590-3P PROMOTES OVARIAN CANCER 
GROWTH AND METASTASIS VIA A NOVEL FOXA2-
VERSICAN PATHWAY 
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ABSTRACT 
miRNAs play important roles in gene regulation, and their dysregulation is associated 
with many diseases, including epithelial ovarian cancer (EOC), which is the fifth leading 
cause of cancer-related death among women. In this study, we determined the expression and 
function of miR-590-3p in EOC. miR-590-3p levels were higher in high-grade carcinoma when 
compared with low-grade or tumors with low malignant potential. Interestingly, plasma levels 
of miR-590-3p were significantly higher in patients with EOC than in subjects with benign 
gynecologic disorders. Transient transfection of miR-590-3p mimics or stable transfection of 
mir-590 increased cell proliferation, migration, and invasion. In vivo studies revealed that mir-
590 accelerated tumor growth and metastasis. Using a cDNA microarray, we identified 
forkhead box A2 (FOXA2) and versican (VCAN) as top downregulated and upregulated genes 
by mir-590, respectively. miR-590-3p targeted FOXA2 3′ UTR to suppress its expression. In 
addition, knockdown or knockout of FOXA2 enhanced cell proliferation, migration, and 
invasion. Overexpression of FOXA2 decreased, whereas knockout of FOXA2 increased 
VCAN mRNA and protein levels, which was due to direct binding and regulation of the VCAN 
gene by FOXA2. Interrogation of the TCGA ovarian cancer database revealed a negative 
relationship between FOXA2 and VCAN mRNA levels in EOC tumors, and high FOXA2/low 
VCAN mRNA levels in tumors positively correlated with patient survival. Finally, 
overexpression of FOXA2 or silencing of VCAN reversed the effects of mir-590. These 
findings demonstrate that miR-590-3p promotes EOC development via a novel FOXA2–
VCAN pathway. 
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INTRODUCTION 
Epithelial ovarian cancer (EOC) is the most common form of ovarian cancer and has 
the highest mortality rate among all gynecologic malignancies [1]. There are no effective early 
screening methods for EOC; thus, most cases are not detected until late stages when the cancer 
has spread to other organs. Ovarian cancer cells detached from primary tumors often settle on 
the peritoneum and omentum, as well as adjacent organs [2]. However, tumor cells have also 
been detected in the blood of patients with ovarian cancer, suggesting an additional 
hematogenous path by which cancer cells invade through blood and lymph vessels to establish 
secondary tumors [3]. 
miRNAs are small noncoding RNAs that regulate gene expression primarily at the 
posttranscriptional levels. miRNA genes are transcribed into primary miRNAs, processed into 
precursor (pre)-miRNAs, and exported from the nucleus. Within the cytoplasm, pre-miRNAs 
are further processed into mature miRNAs [4]. It is well accepted that miRNAs play critical 
roles in many developmental and physiologic events. Moreover, aberrant miRNA expression 
has been implicated in the pathogenesis of human diseases, including cancer [4]. 
miR-590-3p is contained within an intron of the eukaryotic translation initiation factor 
4H gene. miR-590-3p was first reported to enhance cardiomyocyte proliferation and cardiac 
regeneration after myocardial infarction [5]. More recently, the effects of miR-590-3p on 
several types of cancer have been reported [6-8]. Although the role of miR-590-3p in ovarian 
cancer is unknown, an RNA sequencing (RNA-seq) study has identified miR-590-3p as one of 
the miRNAs dysregulated in EOC tumors [9], suggesting its potential role in EOC 
development. 
Forkhead box A2 (FOXA2) is a transcription factor involved in the regulation of 
embryo development, as well as metabolism and homeostasis [10]. Recent studies suggest that 
FOXA2 also plays a role in cancer development. Tumor-suppressive effects of FOXA2 have 
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been reported in pancreatic cancer [11], lung cancer [12, 13], and gastric cancer [14]. In breast 
cancer, both tumor-suppressing [15] and tumor-promoting effects [16] have been found. 
Interestingly, the role of FOXA2 in liver cancer development is sexually dimorphic, with 
tumor-suppressive effects in females and tumor-promoting effects in males [17]. 
Versican (VCAN) is a large proteoglycan and a major component of the extracellular 
matrix. Numerous studies have shown that VCAN is frequently overexpressed in tumor tissues 
and promotes processes associated with tumor development, such as adhesion, proliferation, 
migration, invasion, and angiogenesis [18]. In advanced stage serous ovarian cancer, high 
VCAN expression in the tumor stroma is associated with shorter survival [19], and in vitro 
studies suggest that VCAN promotes ovarian cancer cell invasion [20]. 
The aim of this study was to investigate the role of miR-590-3p in ovarian cancer 
development. Herein, we report that miR-590-3p is upregulated in tumor tissues and plasma 
samples of patients with EOC and exerts tumor-promoting effects. We further demonstrate that 
FOXA2 is a direct target of miR-590-3p and identify FOXA2 as a negative regulator of VCAN. 
Finally, we show that lower FOXA2 and higher VCAN levels in the same tumors are 
significantly associated with decreased survival rates in patients with ovarian cancer. 
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METHODS AND MATERIALS 
 Patient specimen  
Two sets of samples were used in this study. The first set, which contained tissues and 
plasma samples, was collected at Mansoura Oncology Center in Egypt (Supplementary Table 
S1A) with approval by the Institutional Review Board of the American University in Cairo. 
The other set of tumor samples was obtained from the Ottawa Ovarian Cancer Tissue Bank 
(Supplementary Table S1B) through a protocol approved by the Research Ethics Board of The 
Ottawa Hospital (Ottawa, Canada). For the first set of samples, control ovarian tissues were 
taken from women who underwent hysterectomy and/or oophorectomy for benign gynecologic 
conditions. Blood samples were collected prior to surgery. All patients provided written 
informed consent. The studies were conducted in accordance with the ethical guidelines of 
Canadian Tri-Council and U.S. Common Rule. 
  
Cell culture and transient transfection 
EOC cell lines, ES-2, SKOV3.ip1, and HEY, were obtained and cultured, as reported 
previously [21]. The SKOV3.ip1 was transfected with a luciferase plasmid (pMIR-REPORT, 
Ambion) to allow for bioluminescent imaging. OVCAR3 was purchased from ATCC and 
cultured in RPMI1640 media (HyClone) supplemented with 20% FBS and 0.01 mg/mL insulin. 
All cell lines have been authenticated using short tandem repeat profile (IDEXX BioResearch). 
Cells were routinely tested to ensure they were free of Mycoplasma contamination using 
Mycoplasma Detection Kit-QuickTest (BioMake) and DAPI staining. Transient transfection of 
plasmids (0.25–1.5 μg), miRNA mimics, inhibitors, or siRNAs (150–200 nmol/L) was carried 
out in 6-well plates using Lipofectamine 2000 or Lipofectamine RNAiMAX (Life 
Technologies) following the manufacturer's suggested protocols. siRNAs, nontargeting 
negative control (NC), and miR-590-3p/5p mimic were purchased from GenePharma Co. Anti–
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miR-590-3p/5p and its corresponding NC were purchased from RiboBio. Their sequences are 
listed in Supplementary Table S2. The FOXA2 expression plasmid was purchased from 
GenScript. 
 
Generation of mir-590 stable cell lines 
A fragment containing hsa-mir-590 stem-loop sequence was generated using specific 
primers (Supplementary Table S2). PCR was carried out using Phusion DNA Polymerase, and 
the resulting product was cloned into the pRNAT-CMV3.2/Hygro Expression Vector 
(GenScript). Positive clones were selected using PCR and validated by sequencing. The clone 
with the correct sequence was subsequently transfected into ES-2, SKOV3.ip1, and HEY cells. 
To generate control cells, the same cell lines were transfected with pRNAT-CMV3.2/Hygro, 
without the mir-590 insert. Following transfection, cells were cultured with hygromycin (0.6 
mg/mL for SKOV3.ip1 and HEY cells and 0.8 mg/mL for ES-2) to select mir-590–positive 
cells. 
 
RNA extraction, reverse transcription, and real-time PCR 
Total RNA was extracted from cells or tissues using TRIzol reagent (Invitrogen) and 
reverse transcribed into cDNA, as described previously [22]. qRT-PCR was carried out using 
EvaGreen qPCR Master Mix (ABM), following the manufacturer's suggested protocol. The 
levels of mRNAs were normalized to GAPDH. Primer sequences are listed in Supplementary 
Table S2. To measure miR-590-3p and miR-590-5p levels, small RNA–enriched total RNA 
was extracted using TRIzol reagent (Invitrogen) as reported previously [22, 23]. The miR-590 
levels in cells and tissues were measured using TaqMan PCR Kit (Thermo Fisher Scientific) 
and normalized to U6 snRNA. RNA was extracted from plasma samples using Qiagen 
miRNeasy Serum/Plasma Kit. A synthetic C. elegans cel-miR-39 miRNA mimic spike-in was 
51 
 
used as an internal control. Relative quantification of mRNAs and miRNAs were calculated 
using the 2−ΔΔCt method. 
   
Migration, invasion, and proliferation assays 
Transwell migration and invasion assays were performed as described previously [21] 
with the modification that migrated and invaded cell numbers were counted using an automated 
quantification plugin for ImageJ [24]. Cell proliferation assays were conducted using manual 
cell counting or a real-time live-cell imaging system IncuCyte S3 (Essen Bioscience). Briefly, 
transfected cells were detached using Accutase (Corning) and seeded into a 96-well plate at the 
density of 2.5 × 103 cells/well. Four hours after seeding, images were taken every 4 hours for 
68 hours. 
  
Clonogenic assay 
A total of 500 cells, stably overexpressing either mir-590 or its empty vector (EV), were 
seeded in a 6-well plate. After 15 to 20 days, colonies were fixed with 3.7% paraformaldehyde 
for 5 minutes, and stained with 0.05% crystal violet for 30 minutes. Plates were then washed, 
and the number of visible colonies were counted. 
 
Microarray analysis 
Total RNA was extracted from the ES-2 cell line overexpressing mir-590 and its EV-
transfected control cell line (n = 3 wells). The cDNA microarray and subsequent analyses were 
conducted by the Princess Margaret Genomics Centre, Toronto, Canada 
(https://www.pmgenomics.ca/pmgenomics/). Hybridization was carried out using the Human 
HT-12 V4 BeadChip and data were imported in GeneSpring (v13.0) for analysis. The data were 
first normalized using a standard (for Illumina arrays) quantile normalization followed by a 
52 
 
“per probe” median centered normalization. Data were then filtered to remove the confounding 
effect probes that show no signal may have on subsequent analysis. Only probes that were 
above the 20th percentile of the distribution of intensities in 100% of any of the 1 of 2 groups 
were allowed to pass through this filtering. The final set contained 38,146 probes. A one-way 
ANOVA with a Benjamini–Hochberg false discovery rate–corrected P < 0.05 showed 4,259 
significantly varying probes. A post hoc Tukey HSD test was used after the ANOVA and 
resulted in 2,483 significant probes. The microarray dataset has been deposited to the Gene 
Expression Omnibus repository under the accession number GSE113440. Genes that showed 
a difference between the EV and mir-590 groups by 2.0-fold or more were organized into a 
heatmap using the Multi Experiment Viewer (MeV) Microarray Software Suite. The Cancer 
Genome Atlas (TCGA) ovarian cancer dataset in Oncomine (www.oncomine.org) was 
interrogated to determine whether these genes are dysregulated in EOC. 
 
Protein extraction and immunoblotting 
Cell lysates were prepared as described previously [21]. To detect FOXA2, proteins 
were separated by 10% SDS-PAGE gels, then transferred to PVDF membranes (Immobilon-P, 
Millipore Corp.) for 1 hour. To resolve VCAN samples and GAPDH on the same gel, samples 
were loaded into 4% to 15% gradient gels and transferred to PVDF membranes for 14 hours 
using 40 volts in a cold room at 4°C. Membranes were blocked in 5% blocking buffer (5% 
skim milk in Tris-buffered saline and Tween-20) for 1 hour at room temperature and then 
incubated overnight with primary antibody at 4°C. Membranes were subsequently probed using 
horseradish peroxidase–conjugated secondary antibody (1:5,000) at room temperature for 2 
hours. Protein signals were visualized using Luminata Classico Western HRP Substrate (EMD 
Millipore Corp.). FOXA2 antibody was obtained from Cell Signaling Technology (dilution 
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1:1,000), VCAN antibody was obtained from Boster (1:1,000), and GAPDH antibody was 
purchased from Santa Cruz Biotechnology (1:10,000). 
 
Chromatin immunoprecipitation assay 
Chromatin immunoprecipitation (ChIP) assays were conducted as reported previously 
[25]. Briefly, cells were crosslinked and cell lysates were sonicated and precleared with Pierce 
Protein A/G Magnetic Beads (Thermo Fisher Scientific) for 1 hour at 4°C. The samples were 
incubated with fresh magnetic beads conjugated with either FOXA2 antibody or control IgG 
(Cell Signaling Technology) overnight at 4°C. DNA was extracted from the precipitated 
samples using the phenol–chloroform method. To design primers for VCAN, the VCAN gene 
was analyzed for consensus FOXA2-binding sites,  
5′-[AC]A[AT]T[AG]TT[GT][AG][CT]T[CT]-3′, obtained from UniProt [26] using a program 
developed by us (source code available from http://peng.lab.yorku.ca/bioinformatics-tools). 
The VCAN promoter region was predicted using transcription start site–proximal TF-binding 
sites, promoter-associated histone markers (H3K4Me3 and H3K27Ac), and DNase 
hypersensitivity sites from the UCSC Genome Browser [27]. Three sets of primers were 
designed to target: (i) a predicted FOXA2 binding site on the promoter; (ii) an intragenic site 
with two proximal predicted FOXA2-binding sites overlapping an open chromatin region with 
regulatory potential; and (iii) an intragenic site that overlaps an open chromatin region with no 
predicted FOXA2-binding sites, which serves as a negative control. 
 
Luciferase assay 
A fragment of FOXA2 3′ UTR, containing the predicted miR-590-3p–binding site, was 
generated by PCR using specific primers (Supplementary Table S2). The resulting PCR 
amplicon was cloned into pMIR-REPORT, downstream of the luciferase coding sequence. 
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Cells were seeded in 12-well plates at a density of 7.5 × 104 cells/well, transfected with the 
FOXA2 3′ UTR construct, together with miR-590-3p mimics or its NC. At 24 hours after 
transfection, luciferase activity was measured using the Dual Luciferase Reporter Assay 
System (Promega) according to the manufacturer's instructions, as reported previously [23]. 
 
Tumor xenograft assays 
The use of animals for this study was approved by York University Animal Care 
Committee. Five to 6-week-old female CD-1 nude mice were purchased from Charles River 
Laboratories and were housed under sterile conditions in Microisolator cages, fed standard 
chow diet with water, and maintained in a 12-hour light/dark cycle. To study tumor formation, 
mice were injected subcutaneously with 1.5 × 106 control or mir-590 stable ES-2 cells 
suspended in 150 μL PBS. Tumor size was measured every 2 days throughout the course of the 
experiment. The endpoint of the study was determined when tumor size reached 17 mm or if 
the animal showed any sign of sicknesses such as hunched posture, inactivity, hypothermia, or 
ulceration at the tumor site. To study tumor metastasis, two experiments were performed. In 
the first experiment, mice were injected intraperitoneally with 1 × 106 SKOV3.ip1-luc cells 
expressing EV or mir-590, suspended in 200 μL of PBS. Animals were monitored daily and 
the experiment was terminated at day 70 when some of the mice showed excessive abdominal 
distension or moribund. Mice were anaesthetized using Ketamine (100 mg/kg) and Xylazine 
(10 mg/kg; CDMV) and then sacrificed. The number of nodules, as well as tumor weight and 
volume, were determined. In the second experiment, mice were injected with 5 × 
106 SKOV3.ip1-luc control or mir-590 stable cells, and at 8, 16, and 23 days after cell 
inoculation, mice were anaesthetized and injected intraperitoneally with D-luciferin (150 
mg/kg, Thermo Fisher Scientific), and bioluminescence signals were detected using an animal 
imager (ART Optix MX3). 
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Generation of FOXA2 knockout cells 
To knockout FOXA2, two single guide (sg)RNAs targeting 
human FOXA2 (Supplementary Table S2), designed by the Zhang laboratory [28] and cloned 
into pLentiCRISPR v2, were purchased from GenScript. Lentiviral packaging plasmids 
(pMDLg/pRRE and pRSV-Rev) and the envelope plasmid (pMD2.G) was obtained from 
Addgene. To produce virus, 293T cells, seeded at a density of 2.5 × 106 cells/10-cm plate, were 
infected with 20 μg of each of the pLentiCRISPR v2 with or without FOXA2 sgRNA, 10 μg 
of pMDLg/pRRE, 5 μg of pRSV-Rev, and 6 μg of pMD2.G. Supernatants were collected and 
used to infect ES-2 and SKOV3.ip1 cells to generate the control with EV as well as the 
two FOXA2 knockout lines: FOXAΔ1 and FOXAΔ2. After infection, cells were cultured with 
puromycin at a concentration of 1 μg/mL to select infected cells. 
 
TCGA data analysis and bioinformatics 
To investigate the correlation of FOXA2 and VCAN expression with multiple clinical 
attributes, portions of the TCGA Provisional dataset published on June 31, 2016, for ovarian 
serous cystadenocarcinoma (https://cancergenome.nih.gov) were downloaded from 
cBioPortal.org [29]. This dataset contains 603 samples with associated clinical characteristics 
and 307 of those samples have undergone RNA-seq and Illumina HM27 methylation analysis, 
which were used in this study. Investigation of the preceding 2011 dataset was limited as it 
contained fewer samples, no RNA-seq/DNA methylation data, and far fewer clinical attributes. 
For these reasons, we report bioinformatical findings from the more comprehensive provisional 
dataset only. Sample data were aggregated from multiple files into a single comma delimited 
file using a custom C++ program (available from http://peng.lab.yorku.ca/bioinformatics-
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tools) compiled using Microsoft Visual Studio 2015 and analyzed in Microsoft Excel 2016. 
The analysis was independently completed at least twice to ensure a high degree of fidelity. 
To determine the association between FOXA2 or VCAN and the clinical outcomes, 
samples were grouped into FOXA2 or VCAN “low” and “high” expression groups based on 
whether the expression levels were below or above, respectively, the mean value. These groups 
were then divided into subgroups based on the sample SDs from the mean (SD 1.0, SD 1.25, 
SD 1.5) where SD 0.0 represents all samples in the low or high group. In this way, subgroups 
represent increasing extremes of mRNA expression values. The following criteria were used 
to define the groups (Eq. A):  
𝐼𝑓 𝑥𝑖 < ?̅? − (𝑠 ∗ 𝑚) → 𝐿𝑜𝑤 𝑔𝑟𝑜𝑢𝑝 
𝐼𝑓 𝑥𝑖 > ?̅? + (𝑠 ∗ 𝑚) → 𝐻𝑖𝑔ℎ 𝑔𝑟𝑜𝑢𝑝 
Where 𝑥𝑖 represents each sample’s FOXA2 or VCAN mRNA expression value, ?̅? the mean, 𝑠 
the sample standard deviation, and 𝑚 the number of SDs from the mean; SD 1.0 is represented 
by 𝑚 = 1.0.  FOXA2 or VCAN mRNA expression groups and subgroups were calculated 
independently from each other. 
 To examine the effects of anticorrelated FOXA2 and VCAN mRNA expression 
samples, they were first assigned a Δ coefficient to represent the relative difference between 
FOXA2 and VCAN mRNA expression. mRNA expression values were converted to SDs from 
the mean (SDM) and then VCAN SDM was subtracted from FOXA2 SDM for each sample to 
calculate Δ (Eq. B): 
 
∆ =
𝑥𝑖
𝐹𝑂𝑋𝐴2 − ?̅?  𝐹𝑂𝑋𝐴2
𝑠𝐹𝑂𝑋𝐴2
−
𝑥𝑖
𝑉𝐶𝐴𝑁 − ?̅?  𝑉𝐶𝐴𝑁
𝑠𝑉𝐶𝐴𝑁
 
∆ < 0
 
⇒ ↓ 𝐹𝑂𝑋𝐴2, ↑ 𝑉𝐶𝐴𝑁 
∆ > 0
 
⇒ ↑ 𝐹𝑂𝑋𝐴2, ↓ 𝑉𝐶𝐴𝑁 
(B) 
(A) 
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The definition of variables is the same as those described for Eq.A.  
 Samples were shown or hidden based on the criteria above using conditional ‘IF’ 
statements in Excel.  This allowed quick manipulation of groups and subgroups by changing 
𝑚 (Eq. 1) or ranges of ∆.  Data retrieval was then based on samples passing the desired criteria 
and containing queried data (e.g. methylation) and then formatted to be copied to GraphPad. 
Binary data such as ‘Recurred/Progressed’ and ‘Disease-free’ were converted to 1 and 0, 
respectively.  Likewise, clinical attributes for Survival and Invasion indicators were also 
converted to binary; ‘DECEASED’ and ‘Yes’ = 1, ‘LIVING’ and ‘NO’ = 0, respectively.  
 
Statistical analysis 
All in vitro experiments were done at least three times with at least triplicates in each 
group. The results are expressed as mean ± SEM in bar graphs and line graphs. Statistical 
analyses were performed using SigmaStat and GraphPad prism 6. Multiple groups were 
analyzed by one-way or two-way ANOVA, followed by Tukey post hoc test. Student t-test was 
used for comparison between two groups. Clinical samples were presented as box–whisker 
plots and analyzed by Kruskal–Wallis test, followed by Wilcoxon rank test for multiple group 
comparison or Wilcoxon rank test when only two groups were compared. For TCGA clinical 
samples, binary data were analyzed using one-tailed Student t-test. Kaplan–Meier survival and 
disease-free graphs were analyzed using the Mantel–Cox test; P < 0.05 was considered 
statistically significant. 
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RESULTS 
miR-590-3p is upregulated in ovarian cancer and promotes cell growth, migration, and 
invasion 
Using EOC tissue samples collected at Mansoura Oncology Center (Supplementary 
Table S2.1A) and Ottawa Ovarian Cancer Tissue Bank (Supplementary Table S2.1B), we 
found that miR-590-3p levels in grade II/III ovarian tumors were significantly higher than in 
grade I tumors or normal ovarian tissues (Fig. 2.1A). Similarly, miR-590-3p levels were also 
upregulated in high-grade serous tumors when compared with tumors of low malignancy 
potential (Fig. 2.1B). In another histologic subtype of EOC, endometrioid ovarian cancer, high-
grade tumors also had higher miR-590-3p levels than the low-grade ones (Supplementary Fig. 
S2.1A). Circulating miR-590-3p levels were also significantly higher in patients with EOC 
than in subjects with benign gynecologic disorders (Fig. 2.1C). To determine the effect of miR-
590-3p on cell proliferation, migration, and invasion, EOC cell lines ES-2, SKOV3.ip1, and 
OVCAR3 were transiently transfected with miR-590-3p mimic, anti–miR-590-3p, or NCs. 
miR-590-3p significantly increased cell numbers (Fig. 2.1D; Supplementary Fig. S2.1B), 
migration, and invasion (Fig. 2.1E; Supplementary Fig. S2.1C–S2.1E). On the other hand, 
inhibition of miR-590-3p by anti–miR-590-3p resulted in a significant decrease in cell 
proliferation (Fig. 2.1D) and migration (Supplementary Fig. S2.1D). 
 
Stable overexpression of mir-590 enhances tumor development and metastasis 
To further investigate the function of miR-590-3p in EOC development, SKOV3.ip1 
cells expressing luciferase, ES-2, and HEY cells stably transfected with mir-590 or its 
corresponding EV were generated (Supplementary Fig. S2.2A). Real-time PCR revealed that 
both miR-590-3p and miR-590-5p were significantly higher in cells transfected with mir-590, 
when compared with the EV (Supplementary Fig. S2.2B). Overexpression of mir-590 
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significantly enhanced cell proliferation (Fig. 2.1F), invasion (Fig. 2.1G), and colony formation 
(Fig. 2.1H; Supplementary Fig. S2.2C). To confirm that the observed effects of mir-590 were 
due to miR-590-3p and/or miR-590-5p overexpression, we transfected EV and mir-590 cells 
with anti–miR-590-3p, anti–mir-590-5p, or their nontargeting control. Both anti–miR-590-3p 
and anti–miR-590-5p reduced invasion in EV and mir-590 cells in ES-2 cells. However, in 
SKOV3.ip1 cells, only anti–miR-590-3p had a significant effect of cell invasion in the EV 
control group (Fig. 2.1I). 
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Figure 2.1. miR-590-3p is upregulated in EOC and exerts tumor-promoting effects in 
vitro. A, miR-590-3p levels were elevated in higher grade EOC tumors compared with normal 
ovarian tissue or low-grade tumors. RNA was extracted from normal ovary (n = 6), grade 1 
(n = 11), or grade 2/3 EOC samples (n = 9), and miR-590-3p level was determined by real-time 
PCR. B, miR-590-3p levels were higher in high-grade serous ovarian tumors (HG; n = 14) than 
in tumors with low malignancy potential (LMP; n = 16). C, Plasma miR-590-3p levels were 
significantly higher in patients with EOC (n = 13) than in subjects with benign gynecologic 
disorders (n = 6). Data in A–C are converted to log2 and plotted in box–whisker plots. D, miR-
590-3p enhanced cell proliferation. SKOV3.ip1 cells were transiently transfected with NCs, 
miR-590-3p mimic, or anti–miR-590-3p. Cell confluency was monitored by IncuCyte for 68 
hours (n = 7). E, miR-590-3p enhanced cell migration and invasion. ES-2 cells were transiently 
transfected with miR-590-3p or its NC, and transwell migration and invasion were determined 
at 24 hours after transfection (n = 3). F, Stable overexpression of mir-590 increased cell 
proliferation in both ES-2 and SKOV3.ip1 cells when compared with parental or control cells 
transfected with EV (n = 3). G, Cells overexpressing mir-590 invaded faster than cells 
expressing the EV (n = 3). H, In a clonogenic assay, cells overexpressing mir-590 formed more 
and larger colonies than the ones expressing the EV (n = 3). I, Effects of anti–miR-590-3p and 
anti–miR-590-5p on mir-590–induced cell invasion. ES-2 and SKOV3.ip1 cells stably 
transfected with EV or mir-590 were transiently transfected with anti–miR590-3p, anti–miR-
590-5p, or their negative control (anti-NC). Transwell assays were performed (n = 3). Data 
represent median flanked by 25th and 75th percentiles (A–C) and mean ± SEM (D–I). *, P < 
0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Different letters above bars denote 
statistical significance. 
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To determine whether mir-590 affects tumor formation in vivo, ES-2 cells stably 
overexpressing mir-590 or its control vector were injected subcutaneously into female CD-1 
nude mice and tumor size was measured over 21 days. The mir-590 cells formed significantly 
larger tumors at multiple time points measured (Fig. 2.2A). To examine the effect of mir-590 
on metastasis, control and mir-590–expressing SKOV3.ip1 cells were injected 
intraperitoneally into the nude mice. It was observed that mice injected with mir-590 cells had 
a higher number of nodules throughout the peritoneal cavity (Fig. 2.2B) and formed larger 
tumors when compared with the control (Fig. 2.2C). Live animal imaging revealed that mice 
inoculated with mir-590 cells had stronger bioluminescent signals than mice injected with 
control cells (Fig. 2.2D). 
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Figure 2.2. mir-590 promotes tumor formation and metastasis in vivo. A, mir-590 
accelerates tumor growth. ES-2 cells stably transfected with EV or mir-590 were injected 
subcutaneously into female CD-1 nude mice, and tumor volumes were measured (n = 8). B 
and C, mir-590 promotes tumor metastasis. SKOV3.ip1 cells stably transfected with luciferase 
and EV or miR-590 were injected intraperitoneally into CD-1 nude mice and the mice were 
examined at 70 days after tumor cell inoculation. The number of nodules (B) and total tumor 
volumes and weight (C) were significantly higher in mice injected with mir-590 cells when 
compared with the control. D, Bioluminescent imaging of mice inoculated with control or mir-
590 cells. Mice were injected intraperitoneally with SKOV3.ip1 cells expressing the vector or 
mir-590 (n = 5). Bioluminescence images were taken at day 8 to day 23 after injection. Data, 
mean ± SEM. *, P < 0.05; **, P < 0.01. 
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miR-590-3p regulates FOXA2 and VCAN 
To determine the molecular mechanisms by which mir-590 exerts tumor-promoting 
effects on EOC, cDNA microarray was performed. Genes that were either up- or 
downregulated by mir-590 by 2-fold or more were organized into a heatmap (Fig. 2.3A). Genes 
that were downregulated were analyzed for miR-590-3p/5p–binding sites using tools 
at microRNA.org. It was found that most of these genes have predicted miR-590-3p–binding 
sites and a few have predicted miR-590-5p sites (Supplementary Table S2.3A). Interrogation 
of the TCGA dataset revealed that most of the top mir-590–downregulated genes were 
underexpressed in ovarian cancer samples when compared with normal ovary (Supplementary 
Table S2.3A). Among them, FOXA2 is the most strongly downregulated gene that has a miR-
590-3p–binding site and is also downregulated in the TCGA dataset (Supplementary Table 
S2.3A). On the other hand, among all upregulated genes by mir-590, VCAN is the most 
strongly upregulated in the TCGA database (Supplementary Table S2.3B) and known to play 
a role in EOC development [29]. Therefore, we further investigated the expression, regulation, 
and function of FOXA2 and VCAN.  
Using the tumor samples collected from the Ovarian Cancer Tissue Bank at Ottawa 
Research Institute, we found that FOXA2 mRNA levels were significantly lower, whereas 
VCAN mRNA levels showed the opposite trend, in the high-grade tumors than in tumors of 
low malignancy potential (Fig. 2.3B). Real-time PCR and Western blotting confirmed that 
FOXA2 was downregulated in ES-2 and SKOV3.ip1 cells overexpressing mir-590 (Fig. 2.3C). 
FOXA2 mRNA levels were also significantly downregulated in HEY mir-590 stable cells 
(Supplementary Fig. S2.3A). In tumors collected from mice grafted with ES-2 cells, FOXA2 
mRNA and protein levels were also downregulated (Supplementary Fig. S2.3B). Conversely, 
VCAN protein and mRNA levels were higher in mir-590 cells than in the vector controls (Fig. 
2.3D). 
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miR-590-3p targets FOXA2 
To confirm that miR-590-3p directly targets FOXA2, luciferase reporter assays were 
performed. Transient transfection of miR-590-3p mimic or stable transfection of mir-590 
significantly reduced the luciferase activity (Fig. 2.3E). Transient transfection of miR-590-3p 
also reduced FOXA2 mRNA and protein levels, whereas anti–miR-590-3p enhanced FOXA2 
protein levels in ES-2 cells (Fig. 2.3F). Similarly, transfection of the miR-590-3p mimic in 
HEY, SKOV3.ip1, and OVCAR3 cells decreased FOXA2 protein levels (Supplementary Fig. 
S2.3C). 
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Figure 2.3. Regulation of FOXA2 and VCAN by mir-590. A, Heatmap of genes regulated 
by mir-590 revealed by cDNA microarray. Total RNA extracted from ES-2 cells stably 
transfected with mir-590 or EV control were subjected to a cDNA microarray analysis. Genes 
that were ≥2-fold down- or upregulated by mir-590 were included in the heatmap. B, FOXA2 
mRNA levels (left) were significantly lower, whereas VCAN mRNA levels (right) showed an 
opposite trend in high-grade serous ovarian tumors (HG; n = 13) than in tumors with low 
malignancy potential (LMP; n = 15). C, Confirmation of FOXA2 downregulation by mir-590 
using real-time PCR and Western blotting in both ES-2 and SKOV3.ip1 stable 
cells. D, Upregulation of VCAN by mir-590. Overexpression of mir-590 resulted in an increase 
in VCAN protein levels in both ES-2 and SKOV3.ip1 cells (left). Real-time PCR (right) 
revealed higher VCAN mRNA levels in mir-590–expressing in ES-2 cells (n = 3). E, FOXA2 
is a target of miR-590-3p. A predicted miR-590-3p–binding site was found on FOXA2 3′ UTR. 
A luciferase reporter construct containing FOXA2 3′ UTR was generated. In ES-2 cells stably 
transfected with mir-590 (left), or transiently transfected with miR-590-3p (right), the 
luciferase activity was significantly decreased (n = 3). F, Transient transfection of miR-590-3p 
decreased FOXA2 mRNA levels (n = 3) and the protein levels, whereas transfection of anti–
miR-590-3p increased FOXA2 protein levels. Statistical analyses were performed using 
Wilcoxon rank test (B), ANOVA/Tukey test (E, right), or t-test (all others). *, P < 0.05; **, P < 
0.01; ***, P < 0.001; ****, P < 0.0001 versus their respective controls 
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FOXA2 exerts antitumor effects 
To determine the role of FOXA2 in EOC development, we validated two siRNAs that 
decreased FOXA2 mRNA and protein levels (Fig. 2.4A). Transfection of these FOXA2 
siRNAs in EOC cells accelerated proliferation (Fig. 2.4B) and invasion (Fig. 2.4C). To further 
confirm the role of FOXA2 in EOC cells, we used CRISPR/Cas9 gene editing tools to 
knockout FOXA2 in both ES-2 and SKOV3.ip1 cells. Two sgRNAs were used to generate two 
populations of heterogeneous FOXA2 knockout cells, designated as FOXAΔ1 and FOXAΔ2, 
respectively. FOXA2 knockout diminished the expression of FOXA2 (Fig. 2.4D) and resulted 
in increased cell proliferation (Fig. 2.4E), migration (Fig. 2.4F), and invasion (Fig. 2.4G). 
Conversely, transient transfection of FOXA2 into several cell lines resulted in an inhibition of 
cell invasion (Fig. 2.4H; Supplementary Fig. S2.3D). 
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Figure 2.4. FOXA2 exerts antitumor effects in EOC cells. A, Validation of two different 
siRNAs targeting FOXA2. In ES-2 cells transfected with FOXA2 siRNAs, FOXA2 mRNA 
and protein levels were reduced, when compared with cells transfected with a nontargeting 
siRNA (NC). Total RNA and proteins were extracted at 48 hours after transfection. B, 
Knockdown of FOXA2 increased ES-2 cell proliferation. Cell numbers were measured 48 
hours post transfection. C, Knockdown of FOXA2 increased cell invasion in ES-2 and 
SKOV3.ip1 cells. Cells were transfected with NC or one of the FOXA2 siRNAs, and 24 hours 
post transfection, cells were resuspended and an equal number of cells were then placed on the 
top chamber of the transwell inserts. Invaded cells were counted at 18 hours after 
plating. D, Generation of FOXA2 knockout cells using CRISPR/Cas9. Two gRNAs were used 
and both eliminated FOXA2 protein in ES-2 and SKOV3.ip1 cells, as confirmed by Western 
blotting. E–G, Knockout of FOXA2 increased cell proliferation (E), migration (F), and 
invasion (G). H, Transient transfection of FOXA2 plasmid into ES-2 and SKOV3.ip1 cells 
resulted in a decrease in cell invasion. Data, mean ± SEM (n = 3). *, P < 0.05; **, P < 0.01; 
***, P < 0.001; ****, P < 0.0001 versus controls. 
 
 
 
 
 
 
 
 
  
72 
 
FOXA2 inhibits VCAN expression 
Examination of a FOXA2 ChIP-seq dataset produced from mice revealed 
that VCAN was one of the genes enriched in FOXA2 antibody precipitated samples [30]. 
Analysis of the human VCAN gene identified multiple potential FOXA2-binding sites on the 
promoter and gene body; therefore, we tested the possibility that FOXA2 regulates VCAN 
expression. In cells transiently transfected with siRNAs targeting FOXA2, there was an 
increase in VCAN mRNA levels (Fig. 2.5A). In contrast, overexpression of FOXA2 reduced 
VCAN mRNA (Fig. 2.5B) and protein (Supplementary Fig. S2.3D) levels. Furthermore, 
VCAN protein levels were increased in FOXA2 knockout cells and the reintroduction of 
FOXA2 strongly downregulated VCAN levels, as revealed by Western blotting (Fig. 2.5C). 
Finally, ChIP-qPCR assays were performed in ES-2 and SKOV3.ip1 cells using three sets of 
primers designed to target the VCAN promoter site, a potential regulatory site, and a distal 
negative control region with no predicted FOXA2 binding site (NC; Fig. 2.5D, top). In FOXA2 
antibody precipitated samples, enrichment of VCAN DNA was observed in the regions where 
FOXA2-binding sites were predicted when compared with the IgG group, while there was no 
difference between the IgG and FOXA2 antibody groups in the region that had no FOXA2-
binding sites (Fig. 2.5D, bottom). 
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Figure 2.5. FOXA2 regulates VCAN expression. A, ES-2 cells transfected with FOXA2 
siRNAs increased the mRNA level of VCAN. B, In SKOV3.ip1 cells, transient transfection of 
FOXA2 decreased the mRNA level of VCAN. C, Knockout of FOXA2 in ES-2 cells increased 
VCAN protein levels, but this effect was reversed by overexpression of FOXA2. D, FOXA2 
binds to VCAN gene. Top, consensus FOXA2-binding sites were predicted in 
the VCAN promoter and within the gene body. Most of these predicted sites overlap DNA 
regions with histone modifications associated with regulatory potential and DNase 
hypersensitivity regions. Three pairs of primers were designed. The first pair targets the 
FOXA2-binding site in the promoter region (promoter; −1553 bp), the second pair spans two 
intragenic binding sites in a region with regulatory features (regulatory; +43346, +43860), and 
a distal region with no predicted FOXA2-binding site, which serves as a negative control (NC; 
+96586). Bottom, ChIP-qPCR was performed using FOXA2 antibody or IgG in both ES-2 and 
SKOV3.1p1 cells. VCAN DNA was enriched in the promoter, and to a lesser extent, the 
regulatory region (in ES-2), but not in the negative control. Data, mean ± SEM (A, B, 
and D; n = 3). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 versus controls as 
analyzed by ANOVA/Tukey test (A) or t-test (B and D). 
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FOXA2 and VCAN are dysregulated in EOC 
To further investigate the relationship between FOXA2 and VCAN and their 
significance in EOC development, we interrogated an ovarian cancer TCGA database. Initial 
sample-paired analysis of FOXA2 and VCAN mRNA levels displayed a slight negative 
correlation (Pearson: −0.1789, Spearman: −0.2249; Fig. 2.6A, left). To more closely evaluate 
the correlation between FOXA2 and VCAN mRNA levels and their possible effects on various 
clinical attributes, samples were divided into groups based on the deviation of their mRNA 
levels from the mean (Supplementary Fig. S2.4A and S2.4B). Groups were initially created in 
increments of 0.25 SDs. Because of the small sample sizes for groups with greater than 1.5 SD 
from the mean, they were excluded from the analysis. FOXA2 and VCAN mRNA levels were 
negatively correlated in most groups (Supplementary Fig. S2.4C). We adapted the minimal 
signal method from Adorno and colleagues [31] to produce a delta (Δ) coefficient for each 
sample such that a Δ<0 represents samples with relatively low FOXA2 and high VCAN mRNA 
levels and oppositely for Δ>0 (Fig. 2.6A, right; Supplementary Fig. S2.4D). Methylation of 
both FOXA2 and VCAN promoters was also examined. FOXA2 mRNA levels were negatively 
correlated with promoter methylation levels (Pearson: −0.3672, Spearman: −0.4232, P < 
0.0001). Importantly, FOXA2 promoter methylation was positively correlated with VCAN 
mRNA levels (Pearson: 0.1750, Spearman: 0.3934, P < 0.0001; Fig. 2.6B). These samples 
were then divided into low or high groups based on their SD from their mean values 
(Supplementary Fig. S2.5A and S2.5B), and using delta groups with combined FOXA2 and 
VCAN expression profiles (Supplementary Fig. S2.5C). FOXA2 promoter methylation was 
found to be increasingly polarized as both FOXA2 and VCAN mRNA levels moved further 
from the mean (Supplementary Fig. S2.5A and S2.5C, left). In contrast, VCAN promoter 
methylation was not correlated with either FOXA2 or VCAN mRNA levels (Supplementary 
Fig. S2.5B and S2.5C), except for the SD 1.5 high FOXA2 group (Supplementary Fig. S2.5B). 
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Next, we investigated the survival rates and disease-free statuses using the SD groups. 
We observed a trend that high FOXA2 (Supplementary Fig. S2.6A) or low VCAN 
(Supplementary Fig. S2.6B) is associated with longer survival. To determine whether the 
degree of negative correlation between FOXA2 and VCAN is associated with patient survival, 
we examined the delta coefficient groups. In the Δ > 0 group that has high FOXA2 and low 
VCAN mRNA levels, both survival rates and disease-free statuses were increased with a 
median survival increase from 1,170 to 1,539 days (P = 0.0036) and disease-free period from 
455 to 624 days (P = 0.0029; Fig. 2.6C). Interestingly, when examining the degree of vascular 
(VI) and lymphovascular (LVI) invasion, there was a significant positive correlation with 
VCAN and a trend of negative correlation with FOXA2 mRNA levels (Fig. 2.6D and 2.6E). 
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Figure 2.6. Analysis of FOXA2 and VCAN expression patterns in EOC 
tumors. A, FOXA2 and VCAN mRNA levels are negatively correlated in ovarian cancer 
samples. Left, sample-paired FOXA2 and VCAN mRNA levels (log2; RNA-Seq V2 RSEM) 
in TCGA ovarian serous cystadenocarcinoma dataset were negatively correlated (n = 307). 
Pearson, −0.1789; P = 0.017. Spearman, −0.2249; P < 0.0001. Right, FOXA2 and VCAN 
mRNA levels were converted to their distance from the mean in SDs (Z-score). Delta (Δ) values 
were calculated for each tumor sample using SD from the mean of FOXA2 and VCAN mRNA 
expressions to group each sample based on the degree of relative anticorrelation in their 
expression. Delta values less than zero correlate with relatively low FOXA2 and high VCAN 
mRNA expression, whereas values greater than zero correlate with relatively high FOXA2 and 
low VCAN mRNA expression. B, Left, FOXA2 mRNA expression was negatively correlated 
with FOXA2 promoter methylation (Pearson, −0.3672; P < 0.0001; Spearman, −0.4232; P < 
0.0001). Right, VCAN mRNA expression was positively correlated with FOXA2 promoter 
methylation (Pearson, 0.1750; P = 0.0024; Spearman, 0.3934; P < 0.0001). C, Kaplan–Meier 
graphs of either percent survival (left) or percent disease-free (right) were plotted using delta 
groups less than or greater than zero. Delta values less than zero correlate with relatively low 
FOXA2 and high VCAN mRNA expression, whereas values greater than zero correlate with 
relatively high FOXA2 and low VCAN mRNA expression. Median survival was significantly 
greater in the Δ > 0 group based on the log-rank (Mantel–Cox) test; P = 0.0036. Δ < 0: 1,169.7 
d (n = 159); Δ > 0: 1,539.3 d (n = 147). The median time of disease-free status was significantly 
longer in the Δ > 0 group based on the log-rank (Mantel–Cox) test; P = 0.0029. Δ < 0: 455.4 d 
(n = 159); Δ > 0: 624.9 d (n = 147). D and E, Association between the proportion of subjects 
that were positive for vascular (VI; left) and lymphovascular (LVI; right) invasion indicators 
and VCAN or FOXA2 mRNA levels. Data, mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 
0.001. 
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The FOXA2–VCAN pathway mediates mir-590 effect 
To confirm that the downregulation of FOXA2 and upregulation of VCAN contribute 
to the tumor-promoting effects of mir-590, rescue experiments were performed. We observed 
that overexpression of FOXA2 significantly reduced the ability of mir-590 to enhance cell 
migration and invasion (Fig. 2.7A). In addition, we determined whether silencing of VCAN 
would abolish the tumor-promoting effects of FOXA2 knockout. FOXA2 knockout cells 
expressed higher VCAN levels and significantly increased cell migration and invasion. 
However, these effects were significantly reduced when VCAN was knocked down in 
SKOV3.ip1 (Fig. 2.7B) and ES-2 (Fig. 2.7C) cells. Knockdown of VCAN also reduced the 
stimulatory effects of mir-590 on cell proliferation and invasion (Fig. 2.7D). 
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Figure 2.7. FOXA2 and VCAN mediate the effects of mir-590 in EOC cells.  
A, Overexpression of FOXA2 in SKOV3.ip1 cells reversed the effect of mir-590. Control (EV) 
or mir-590 stable cells were transfected with either the control plasmid vector (pcDNA) or 
FOXA2-expressing plasmid. Overexpression of FOXA2 reduced the effects of mir-590 on 
invasion. B, Silencing of VCAN by siRNA reversed the effects of FOXA2 knockout. Top, 
confirmation of VCAN knockdown by siRNA using Western blot analysis. Knockdown of 
VCAN significantly reduced cell migration (middle) and invasion (bottom) 
in FOXA2 knockout SKOV3.ip1 cells. C, In ES-2 cells, knockdown of VCAN attenuated the 
effect of FOXA2 knockout on cell proliferation (top), migration (middle), and invasion 
(bottom). D, Knockdown of VCAN reduced the effects of mir-590 on cell proliferation (left) 
and invasion (right). Statistical analyses were performed using ANOVA/Tukey test and groups 
significantly different from each other are denoted by a different letter. 
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DISCUSSION 
In this study, we provided strong evidence to support a tumor-promoting role of miR-
590-3p in ovarian cancer cells. We demonstrated that overexpression of miR-590-3p or its 
precursor, mir-590, significantly increased cell proliferation, migration, invasion, and colony 
formation in vitro. In addition, mir-590 promoted tumor growth and metastasis in vivo. 
Moreover, miR-590-3p levels were significantly elevated in high-grade EOC tumors when 
compared with normal ovaries or lower grade tumors. Finally, miR-590-3p plasma levels were 
higher in patients with EOC than in subjects with benign gynecologic disorders. These findings 
suggest that higher miR-590-3p is associated with a more aggressive disease. 
Although the role of miR-590-3p in EOC has not previously been established, several 
studies have reported both tumor-promoting and tumor-suppressive effects of miR-590-3p in 
other types of cancer. For example, miR-590-3p promotes cell proliferation and invasion in T-
cell acute lymphoblastic leukemia by inhibiting RB1 [6] and in colorectal cancer by targeting 
the Hippo pathway [7] and by promoting β-catenin signaling [32]. Similarly, tumor-promoting 
effects of miR-590-3p were observed in glioblastoma [33]. In contrast, miR-590-3p suppresses 
hepatocellular carcinoma growth [34] and inhibits proliferation and migration in bladder cancer 
cells [35]. In this study, we demonstrated that miR-590-3p enhanced colony formation, cell 
proliferation, migration, and invasion in vitro, and stimulated tumor growth and metastasis in 
vivo. These findings strongly support a tumor-promoting role of miR-590-3p in EOC. The 
differential role of miR-590-3p reported in different types of cancer is likely due to the 
differential targeting of genes by miR-590-3p and/or differential effects of its target genes. 
Indeed, we examined several reported target genes responsible for the antitumor effects of miR-
590-3p, such as ZEB1 and ZEB2, and did not observe an inhibition by miR-590-3p or mir-590 
in EOC cells. On the other hand, we found that DKK1, which was reported to be targeted by 
miR-590-3p in colon cancer [32], was strongly downregulated in our mir-590 cells. In addition, 
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the tumor-promoting effects of mir-590 observed in our study could also be attributed to miR-
590-5p overexpression. We observed that both anti–miR-590-3p and anti–miR-590-5p 
attenuated the effect of mir-590, suggesting that miR-590-5p is also involved in EOC 
development. 
In this study, we identified FOXA2 as a direct target of miR-590-3p and provided 
several lines of evidence to support a tumor-suppressive role of FOXA2 in EOC. First, FOXA2 
mRNA levels were significantly downregulated in high-grade tumors when compared with 
tumors of low malignancy potential, suggesting that FOXA2 expression is associated with a 
less aggressive phenotype. Second, silencing of FOXA2 expression promoted cell 
proliferation, migration, and invasion, whereas overexpression of FOXA2 had the opposite 
effects. Finally, higher FOXA2 appeared to be associated with better patient survival. These 
findings are consistent with a previous study that identified FOXA2 as one of the 26 genes 
enriched in differentiated ovarian tumors with better prognosis [36]. The results are also in 
agreement with studies in lung cancer, which demonstrate that FOXA2 is a strong inhibitor of 
metastasis with decreased expression levels during cancer progression [12, 13]. Similarly, 
FOXA2 has been reported to suppress EMT and metastasis in breast cancer [15]. However, 
FOXA2 expression in triple-negative/basal-like breast carcinoma is positively associated with 
relapse and promotes cancer development [16]. Interestingly, in a mouse model of liver cancer, 
Foxa2 and Foxa1 suppress or promote liver cancer development, depending on whether they 
interact with estrogen receptor α (ERα) or androgen receptor, respectively [17]. This study also 
revealed that SNPs at FOXA2-binding sites, which impair the binding of both FOXA2 and 
ERα to their targets, correlate with liver cancer development in women. Thus, it is possible that 
the dual function of FOXA2 in cancer development is dependent, at least in part, on its 
interacting partners. It remains to be determined which factor(s) FOXA2 interacts with to exert 
the tumor-suppressive effects in EOC. 
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Findings from the current study identified a novel relationship between FOXA2 and 
VCAN. We demonstrated that knockdown or knockout of FOXA2 enhanced, whereas 
overexpression of FOXA2 reduced, VCAN expression. In addition, ChIP-qPCR results showed 
that FOXA2 bound to the VCAN gene. These findings strongly suggest that FOXA2 is a 
transcriptional repressor of VCAN. This notion is further supported by the expression patterns 
of FOXA2 and VCAN in EOC tumor samples, which reveal a negative correlation between 
FOXA2 and VCAN mRNA levels. Importantly, we found that high FOXA2 and low VCAN 
mRNA levels in the same tumor sample were significantly associated with longer patient 
survival. Knockdown of VCAN reduced cell proliferation, migration, and invasion, supporting 
a tumor-promoting role of VCAN. It has been reported that VCAN can be produced from both 
ovarian cancer cells [37] and cancer-associated fibroblasts [20]. Because the tumor samples in 
the TCGA database most likely contain both cancer and fibroblastic stromal cells, it remains 
to be determined whether a negative relationship between FOXA2 and VCAN exists in both 
cancer and stromal cells. 
Several isoforms of VCAN, namely V0, V1, V2, and V3, with molecular weights of 
approximately 370, 263, 180, and 74 kDa, respectively, are generated by alternative splicing 
[38]. Although V0 and V1 isoforms promote cancer development in many types of cancers, V2 
and V3 isoforms have been reported to have antitumor effects [39]. Studies in EOC tumor 
samples revealed that V1 is the most abundant isoform [19]. The VCAN antibody that we used 
in this study detected several bands with molecular weights between 245 and 135 kDa. The 
intensity of all bands was reduced by the VCAN siRNA, indicating that they are all related to 
VCAN. Based on the molecule weight, the V3 isoform is not detected in our Western blots. It 
has been reported that in several EOC cell lines, including SKOV3 and OVCAR3, V2 isoform 
is not expressed [37]. In addition, V1 isoform can be processed into smaller fragments [40]. 
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Thus, it is possible that miR-590-3p and FOXA2 regulate the expression of V1, and possibly 
V0. 
Although it is widely believed that EOC metastasis occurs mainly within the peritoneal 
cavity [2], recent studies suggest that ovarian cancer cells can also spread via hematogenous 
metastasis [3]. In our analysis of VCAN levels in patients with ovarian cancer, we found that 
high VCAN levels were positively correlated with an increase in vascular and lymphovascular 
invasion indicator in the same samples. These observations, together with the finding that 
VCAN promotes invasion [20] and metastasis [37] in ovarian cancer, raise the interesting 
possibility that VCAN may play an important role in promoting hematogenous and lymphatic 
dissemination of EOC tumors. 
One of the limitations of this study is the comparison of gene expression between tumor 
tissues and normal ovary or between tumors of different grades. EOC is a highly heterogeneous 
disease consisting of at least five histologic subtypes, high-grade serous carcinoma (HGSC), 
endometrioid carcinoma, clear cell carcinoma (CCC), low-grade serous carcinoma, and 
mucinous carcinoma, with HGSC accounting for 70% to 74% of EOC [41]. The different 
subtypes of EOC have distinct molecular features and tissue origins. It is believed that most 
HGSC originate from the fallopian tube epithelium, but some HGSCs may still arise from the 
ovarian surface epithelium [41]. The TCGA database contains data from ovarian serous 
cystadenocarcinoma and normal ovary, and therefore, we compared the expression of genes 
regulated by mir-590 between these two groups. This comparison is not ideal as most ovarian 
carcinomas originate outside the ovary. We therefore also compared miR-590-3p, FOXA2, and 
VCAN levels between the high-grade and low-grade tumors. However, such comparisons also 
have drawbacks because high- and low-grade tumors may have different tissue origins. Thus, 
we cannot exclude the possibility that the difference in gene expression patterns observed 
between carcinoma and normal ovary or between different grades of tumors may reflect the 
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different tissue origins. Nevertheless, the higher level of miR-590-3p in the more aggressive 
higher grade tumors, together with the finding that miR-590-3p promotes EOC cell invasion in 
vitro and metastasis in vivo, strongly suggests that miR-590-3p expression is associated with a 
more aggressive behavior of EOC. Our finding that plasma miR-590-3p levels were higher in 
patients with ovarian cancer than in control subjects further supports the notion that miR-590-
3p is dysregulated during ovarian cancer development. However, it is not clear which factor(s) 
triggers the dysregulation of miR-590-3p during EOC development. A recent study reported 
that hypoxia increased miR-590-5p expression to promote colon cancer metastasis [42]. It 
remains to be investigated whether miR-590-3p is also induced by hypoxia. 
ES-2 and SKOV3 cells are commonly used in ovarian cancer research. Most of the 
experiments in this study were conducted using ES-2 and SKOV3.ip1. SKOV3.ip1 was 
established from the ascites of a nude mouse injected intraperitoneally with SKOV3 cells [43] 
that is known to be a model for endometrioid carcinoma [41]. ES-2 originated from a CCC 
[44]; however, a recent study has placed ES-2 into the category of probably HGSC [45]. ES-2 
is now listed as a cell line with mixed feature [41]. Because most of the samples used for 
bioinformatics analysis to determine the correlation between FOXA2/VCAN and patient 
survival were done using the TCGA dataset, which likely contains mostly HGSC tumors, we 
repeated some of the experiments in a HGSC cell line, OVCAR3 [41] and observed that, similar 
to ES-2 and SKOV3.ip1 cells, miR-590-3p enhanced cell invasion and decreased FOXA2 
expression. On the other hand, FOXA2 suppressed cell invasion and inhibited VCAN 
expression. We have also obtained limited, but similar, results from the HEY cell line, which 
has also been used as a model for HGSC [46]. Based on these findings, it is possible that the 
miR-590-3p–FOXA2–VCAN pathway is preserved in multiple subtypes of EOC. 
In summary, our study characterizes a previously unreported role of miR-590-3p in 
promoting EOC development in part by targeting FOXA2. We also provide evidence to support 
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a novel tumor-suppressive role of FOXA2 in EOC via inhibition of VCAN expression. Finally, 
our findings that low FOXA2/high VCAN mRNA levels in EOC tumors correlate with poor 
survival suggest that these genes may be prognostic markers for this deadly disease. 
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Fig. S2.1. miR-590-3p exerts tumor-promoting effects.  A, miR-590-3p is upregulated in 
high grade (HG) compared with low grade (LG) endometrioid ovarian tumors (n=5). B, miR-
590-3p enhances cell growth. SKOV3.ip1 cells were transiently transfected with non-targeting 
control (NC) or miR-590-3p mimic and cell numbers were counted at 48h after transfection.  A 
mock transfection (with transfection reagents only) was also performed. C, miR-590-3p 
promotes migration in a wound-healing assay. ES-2 (left) or SKOV3.ip1 (right) cells were 
transfected with miR-590 or NC, or with transfection reagents only (mock). Cells transfected 
with miR-590-3p migrated faster than control cells. D, miR-590-3p promotes cell migration in 
a transwell migration assay. SKOV3.ip1 cells were transiently transfected with control or miR-
590-3p mimic (left) or anti-miR-590-3p (right), and transwell migration assays were carried 
out.  miR-590-3p increased, while anti-miR-590-3p decreased the number of cells migrated 
through the pores on the transwell inserts. E, miR-590-3p increases OVCAR3 cell migration 
and invasion. Cells were transfected with NC or miR-590-3p and transwell migration (left) and 
invasion (right) assays were performed. Data represent mean ± SEM (n=3). * p < 0.05, **, p < 
0.01, *** p < 0.001, **** p < 0.0001 vs. controls. 
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Fig. S2.2. Generation of cells stably expressing mir-590.  A, mir-590 expression plasmid was 
generated by subcloning the mir-590 stem-loop sequence into the pRNAT-CMV3.2/Hygro 
expression vector. B, Levels of miR-590-3p and -5p in ES-2, SKOV3.ip1 and HEY cells stably 
transfected with mir-590 or the empty vector (EV) were measured by qRT-PCR. Different 
letters denote statistical significant. C, mir-590 overexpression increased colony formation in 
SKOV3.ip1 cells (n=3). ** p < 0.01 vs. empty vector control (EV). 
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Fig. S2.3. Regulation of FOXA2 by miR-590-3p and effects of FOXA2 on cell invasion 
and VCAN expression. A, FOXA2 mRNA levels were reduced in HEY cells stably transfected 
with mir-590. B, FOXA2 mRNA and protein levels were down-regulated in tumors collected 
from mice grafted with control (EV) or mir-590-overexpressing ES-2 cells. C, Transient 
transfection of miR-590-3p decreased FOXA2 protein levels. D, Transient transfection of miR-
590-3p into OVCAR3 cells resulted in a decrease in cell invasion (left) and VCAN protein 
levels (right). ** p < 0.01 and *** p < 0.001. 
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Fig.  S2.4.  Analysis of FOXA2 and VCAN expression in TCGA ovarian cancer database.  
A, Grouping of tumor samples based on their standard deviation (SD). Tumors were divided 
into groups based on either FOXA2 (top) or VCAN (bottom) mRNA expression (n = 307). The 
Low group (green) represents samples whose mRNA levels are less than the mean and the High 
group (red) greater than the mean.  The SD 0.0 subgroups represent all samples less than (Low 
group) or greater than (High group) the mean.  SD 1.0, 1.25, and 1.5 subgroups exclude samples 
whose mRNA levels are closer to the mean than 0.0, 1.0, or 1.25 SDs. Boxes represent 25
th
 and 
75
th
 percentiles demarcated by the median. B, Frequency histograms of SD groups for FOXA2 
(blue) and VCAN (orange) using a bin width of 1.0. C, FOXA2 and VCAN mRNA expression 
(log2) plotted against VCAN and FOXA2 groups, respectively.  FOXA2 and VCAN mRNA 
expression were significantly negatively correlated throughout most SD subgroups. D, 
Grouped box and whiskers plot of FOXA2 and VCAN mRNA expression levels converted to 
SDs from the mean.  Data is organised into Delta (Δ ) groups ranging from -4 to +4, representing 
lower and upper limits respectively. A Δ < 0 indicates samples with relatively low FOXA2 and 
high VCAN mRNA levels and Δ > 0 represents samples with relatively high FOXA2 and low 
VCAN. * p < 0.05, ** p < 0.01, *** p < 0.001. 
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Fig. S2.5.  Relationship between FOXA2 and VCAN methylation status and their mRNA 
levels.  A, FOXA2 promoter methylation is negatively correlated with FOXA2, but positively 
correlated with VCAN, mRNA levels. The proportion of FOXA2 promoter CpG methylation 
was significantly lower in the high FOXA2 expression group and across all high FOXA2 
subgroups (left panel).  FOXA2 promoter methylation plotted against low and high VCAN 
mRNA expression groups showed a significant positive correlation with VCAN mRNA 
expression. Methylation data was produced through the Illumina Infinium Human Methylation 
27 (HM27) array. B, VCAN promoter methylation is not correlated with either FOXA2 or 
VCAN mRNA expression levels with the exception of FOXA2 High SD 1.5 subgroup. C, Delta 
groups show a significant negative correlation of FOXA2 promoter methylation and mRNA 
expression levels.  Green bars represent relatively low FOXA2 and high VCAN mRNA 
expression levels and red bars relatively high FOXA2 and low VCAN mRNA expression 
levels.  There is no correlation between VCAN promoter methylation and the FOXA2/VCAN 
mRNA levels. Data represent mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 
0.0001. 
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Fig. S2.6. Kaplan-Meier survival plots of all standard deviation groups. A, High FOXA2 
groups show a trend of increased survival excluding SD 1.5.  Low FOXA2: 1066.5 – 1089.9 
days, High FOXA2: 1309.8 – 1773 days.  B, No difference in survival was observed until the 
VCAN SD 1.5 group where low VCAN mRNA expression was correlated with increased 
survival.  Low VCAN: 1075.2 – 1378.8 days, High VCAN: 775.5 – 1260.6 days. P-values were 
calculated using the Log-rank (Mantel-Cox) test. *P < 0.05. 
  
100 
 
Table S2.1: Clinical samples used in this study. 
A. Tumor samples from Mansoura Oncology Center 
Grades/stage/subtype Tissue Samples   Plasma Samples   
Histological Subtypes   
Serous 18 13 
Endometrioid 1 0 
Mucinous 1 0 
FIGO Stages   
IB 4 2 
IIB 3 1 
IIIC 10 8 
IV 3 2 
Histological Grade   
Grade I 11 6 
Grade II 5 5 
Grade III 4 2 
B. Tumor samples from Ottawa Ovarian Cancer Tissue Bank 
Sample ID Stage Histological Subtypes 
H1 IIIC Serous high grade 
H2 IIC Serous high grade 
H3 IIC Serous high grade 
H4 IIC Serous high grade 
H5 III Serous high grade 
H6 IIC Serous high grade 
H7 IIIC Serous high grade 
H8 IIIC Serous high grade 
H9 IIIC Serous high grade 
H10 IIC Serous high grade 
H11 IIIC Serous high grade 
H12 IIIC Serous high grade 
H13 IIIB Serous high grade 
L1 IC LMP 
L2 I LMP 
L3 IA LMP 
L4 Not identified LMP 
L5 III LMP 
L6 Not identified LMP 
L7 Not identified LMP 
L8 Not identified LMP 
L9 IIIA LMP 
L10 IIIA LMP 
L11 Not identified LMP 
L12 I LMP 
L13 IIIA LMP 
L14 Not identified LMP 
L15 III LMP 
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Table S2.2: Oligonucleotides used in this study. 
Name Sequences Source* 
hsa-miR-590-3p mimic  
5′- UAAUUUUAUGUAUAAGCUAGU -3′ 
3′- AUUAAAAUACAUAUUCGAUCA -5′ 
 
GenePharma 
hsa-miR-590-5p mimic 
5′- GAGCUUAUUCAUAAAAGUGCAG -3′ 
3′- CUCGAAUAAGUAUUUUCACGUC -5′ 
 
GenePharma 
hsa-anti-miR-590-3p mimic 5′- ACUAGCUUAUACAUAAAAUUA -3   RiboBio 
hsa-anti-miR-590-5p mimic  5′- CUGCACUUUUAUGAAUAAGCUC -3′   
 
RiboBio 
FOXA2 PCR primers  
F 5′-TCTTAAGAAGACGACGGCTTCAG-3′ 
R 5′-TTGCTCTCTCACTTGTCCTCGAT-3′ 
[1] 
VCAN PCR primers  
F 5′- GTGACTATGGCTGGCACAAATTCC-3′ 
R5′- GGTTGGGTCTCCAATTCTCGTATTGC-3′ 
[2] 
GAPDH PCR primers 
F 5′-AAGGTCATCCCTGAGCTGAAC-3′ 
R 5′-ACGCCTGCTTCACCACCTTCT-3′ 
 
FOXA2 siRNA1  
5′-  AAAUGGACCUCAAGGCCUAtt-3′ 
3′-ttUUUACCUGGAGUUCCGGAU -5′ 
[3] 
FOXA2 siRNA2  
5′-   GAACACCACUACGCCUUCAtt-3′ 
3′ -ttCUUGUGGUGAUGCGGAAGU -5′ 
[3] 
VCAN siRNA  
5′-  GCUGAACCCAUCUGCAUAtt-3′ 
3′-ttCGACUUGGGUAGACGUAU -5′ 
 
Non-targeting siRNA  
5′ -  UUCUCCGAACGUGUCACGUtt-3′ 
3′ -ttAAGAGGCUUGCACAGUGCA -5′ 
GenePharma 
VCAN ChIP (Promoter) 
F 5′- AAGGTTGAAGTCTGATTCTGC-3′  
R 5′- CTTTTGTTATTTATCAGCCCTCTGC-3′ 
 
VCAN ChIP (Regulatory) 
F 5′- GTTGCTTGACTTCACCCTTACC-3′  
R 5′- CCATGAATCATAAGACCTCCCC-3′ 
 
VCAN ChIP (NC) 
F 5′- AGCAAAATCAAAGCATCCTAGC-3′  
R 5′- GAATGTCTGATACCCACAGGC-3′ 
 
mir-590 (clone) 
F 5′ -CTGAACAGGTGACGACTACC-3′ 
R 5′ -AACTTCTATAACACCTGCGA-3′ 
 
FOXA2 (3’UTR clone) 
F 5′ -TACTGTGTAGACTCCTGCTTCTT-3′ 
R 5′ -TATGTCTGAAAATTTTATTAATA-3′ 
 
FOXA sgRNA 1 
(CRISPR/Cas9) 
 5′ -CATGAACATGTCGTCGTACG-3′  
Genscript 
FOXA sgRNA2 
(CRISPR/Cas9) 
5′ -AAGGGCACGAGCCGTCCGAC-3′ 
Genscript 
 
* All siRNAs taken from cited references or designed by us were synthesized by GenePharma.  All primers, 
designed by others or us were ordered from Sigma.  
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Table S2.3: Protein coding genes regulated by mir-590 and their expression profile in TCGA 
ovarian cancer dataset on Oncomine. 
A: Down- regulated genes 
Gene symbol FC (mir/EV) # of -3p 
binding 
# of -5p 
binding 
Dysregulation 
in EOC 
p-value 
TMEM51 -2.011 1 0 -1.159 0.118 
MBP -2.107 0 0 -2.776 3.03 x 10-6 
EFEMP1 -2.116 6 0 -7.146 3.5 x 10-7 
HIST1H2BK -2.158 0 1 1.498 3.58 x 10-5 
FLJ40504 -2.222 0 0 N/A N/A 
TFAP2C -2.299 0 1 2.390 2.96 x 10-4 
ID3 -2.354 1 0 -2.263 0.001 
DKK1 -2.411 1 0 1.176 0.007 
LOX -2.476 4 1 1.694 9.59 x 10-4 
UCA1 -2.555 1 1 N/A N/A 
CBS -2.620 0 0 2.658 0.001 
SIRPA -3.256 1 0 -1.619 0.014 
ANKRD1 -5.436 0 0 1.093 0.046 
FOXA2 -6.113 1 0 -2.269 6.26 x 10-4 
BEX1 -6.209 0 0 -3.449 0.002 
B: Up- regulated genes 
Gene symbol FC (mir/EV) Dysregulation in EOC p-value 
PAGE5 18.106 N/A N/A 
HBBP1 4.598 -1.037 0.184 
LCLAT1 3.223 N/A N/A 
ADORA1 2.495 1.159 0.005 
SERPINB7 2.231 1.247 1.51 x 10-4 
VCAN 2.230 3.744 1.03 x 10-6 
IL1RAPL1 2.103 -1.016 0.401 
CCDC147 2.075 N/A N/A 
FLJ21986 2.048 -1.440 0.007 
CXCL5 2.041 1.176 3.77 x 10-4 
 
N/A: No data available from TCGA database 
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ABSTRACT 
Ovarian cancer is one of the leading causes of cancer death among women around the 
world. MicroRNAs (miRNAs) are small non-coding RNAs that interact with the 3’ untranslated 
region (3ʹ UTR) of target genes to repress their expression.  We have previously reported that 
miR-590-3p promotes ovarian cancer development in part by targeting FOXA2. In this study, 
we investigated other target genes of miR-590-3p and identified cyclin G2 (CCNG2) as a direct 
target of miR-590-3p. Transient transfection of miR-590-3p decreased the luciferase activity 
of a reporter containing CCNG2 3’UTR and CCNG2 mRNA levels. Stable overexpression of 
mir-590 also reduced CCNG2 mRNA and protein levels. miR-590-3p promoted cell 
proliferation, migration and invasion.  In hanging drop cultures, overexpression of mir-590 
induced formation of compact spheroids.  Silencing of CCNG2 expression mimicked, while 
overexpression of CCNG2 reversed, these effects of miR-590-3p. Since we have shown that 
CCNG2 suppresses β-catenin signaling, we investigated if miR-590-3p regulates β-catenin 
activity. In TOPflash luciferase reporter assays, mir-590 increased β-catenin/TCF 
transcriptional activity and overexpression of CCNG2 attenuated the effect of mir-590. In 
addition, mir-590 increased the total β-catenin but decreased phospho-β-catenin levels.  Taken 
together, these results suggest that miR-590-3p promotes ovarian cancer development, in part 
by directly targeting CCNG2 to enhance β-catenin activity.     
 
 
 
 
 
  
106 
 
INTRODUCTION 
Ovarian cancer is the most lethal cancer of the female reproductive system and is one 
of the leading causes of cancer death in women [1]. There are many types of ovarian cancers, 
which are grouped into three categories; epithelial, stromal, and germ cell cancer.  Epithelial 
ovarian cancer (EOC) is the most common form, representing approximately 90% of ovarian 
cancer cases [1] and the current treatment for advanced ovarian cancer is not very effective and 
many patients relapse [2]. One of the reasons for the patient’s high mortality rate is the lack of 
effective early screening methods. In the majority of EOC cases, the disease is usually 
discovered when cancer has already disseminated outside the pelvis and spread throughout the 
abdominal cavity [3]. Another reason is due to the asymptomatic characteristics of EOC, which 
include the bloated feeling, a symptom that is frequently confused with unrelated diseases [4, 
5]. This bloating is due to the accumulation of fluid in the peritoneal cavity corresponding to 
the formation of the malignant ascites [6]. Within the ascites fluid, malignant cells may present 
as single cells or aggregated spheroids. These spheroids were found to be highly resistant to 
many chemotherapeutic agents [7]. Although the precise mechanism involved in the production 
of excessive peritoneal fluid is still unclear [8-10], it is believed that the change in the cell 
behaviour required for compact spheroid formation may also contribute in the promotion of 
ovarian cancer progression [11, 12]. To study this mechanism in vitro, researchers developed 
the  hanging drop culture system to monitor spheroid formation [12].  It has been reported that 
formation of tighter and more compact spheroids is associated with more aggressive EOC 
phenotypes [13].  
 MicroRNAs (miRNAs) are small non-coding RNAs that perform diverse functions 
within cells by regulating gene expression. miRNAs are typically 18-22 nucleotides in length 
and selectively target messenger RNA (mRNA) through complementary binding to the 3ʹ UTR 
of target mRNAs. Depending on the degree of the complementarity between miRNA and its 
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target mRNA sequence, miRNA with the help of AGO2-dependent slicer, a component of RISC 
complex, can cleave highly complementary target mRNAs, whereas miRNAs with lower 
complementarity to their target mRNAs reduce mRNA stability and inhibit translation  [14]. 
Many studies have shown that miRNAs play an important role in determining cell fate, 
controlling cell proliferation [15, 16], migration, invasion, differentiation, as well as cell death 
[17, 18]. Moreover, aberrant miRNA expression has been implicated in the pathogenesis of 
human neurodegenerative disorders, viral and metabolic diseases, as well as cancer [19, 20].  
MicroRNA-590-3p (miR-590-3p) has been reported to exert both oncogenic and anti-
oncogenic effects in various types of cancer [21]. Recently, we have reported that miR-390-3p 
has tumor-promoting effects on EOC cells. We found that miR-590-3o levels were elevated in 
clinical samples collected from patients with high grade carcinoma, and miR-590-3p 
overexpression increased cell proliferation, migration, invasion and colony formation in 
several ECO cell lines, in vitro, and promoted tumor growth and metastasis in vivo. In addition, 
Forkhead box A2 (FOXA2) was identified as a direct target for miR-590-3p [21]. However, 
additional target genes that may be involved in ovarian cancer development remain to be 
identified. 
 Cyclin G2 (CCNG2), a protein encoded by CCNG2 gene, belongs to a group of 
unconventional cyclins that play a role in maintaining the quiescent state and cell cycle arrest 
[11, 12], and has more recently been identified as a potential tumor suppressor [22].  It has 
been observed that CCNG2 levels are inversely correlated with cancer cell progression in breast 
[23], thyroid [24], oral [25], gastric cancers [26], and acute leukaemia [27].  Moreover, CCNG2 
levels are increased during growth inhibition [28] and cell differentiation [29]. Previous studies 
from our lab have shown that CCNG2 reduces cell proliferation and is highly unstable in EOC 
cells [30].  More recently, we found that CCNG2 inhibits epithelial-to-mesenchymal transition, 
cell migration, invasion, and spheroid formation, in vitro, as well as tumor formation and 
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metastasis in vivo. We also identified a major mechanism by which CCNG2 exerts these anti-
tumor effects is via disrupting Wnt/β-catenin signaling [22].  
Canonical Wnt signaling pathway plays important roles in many developmental and 
physiological processes. Its dysregulation is highly associated with cancer development [31]. 
In the absence of Wnt signaling, β-catenin is localized in the cytoplasm, and is recruited to the 
destruction complex, which consists of Axin and APC that form a structural scaffold to bind β-
catenin. β-catenin is subsequently phosphorylated by CK1 and glycogen synthase kinase-3β 
(GSK3β). In the destruction complex, GSK3β also phosphorylates APC, increasing its affinity 
for β-catenin binding, and causing dissociation from Axin. Phosphorylated cytosolic β-catenin 
is then ubiquitinated by β-transduction repeat-containing protein E3 ubiquitin protein ligase (β-
TrCP) [32, 33].  
In the presence of Wnt signalling, extracellular Wnt ligand binds the membrane 
receptor, Frizzled (FZ), which leads to phosphorylation of low-density lipoprotein receptor-
related protein (LRP) co-receptor. When LRP is phosphorylated, it induces the translocation of 
the destruction complex closer to the membrane. At the new location, Dishevelled (DVL) 
interacts with LRP leading to the activation of DVL and inactivation of GSK3β, causing it to 
dissociate from Axin and hence, preventing β-catenin phosphorylation and degradation. 
Stabilized β-catenin accumulates in the cytoplasm and translocates into the nucleus where it 
functions as a coactivator.  In the nucleus, β-catenin interacts with TCF/LEF transcription 
factors to regulate target gene expression [32, 33]. Several studies have reported that this 
pathway promotes ovarian cancer stem cell self-renewal [34, 35], chemoresistance [36], and 
metastasis [37].  In a previous study, we have shown that CCNG2 inhibits LRP6 and DVL2, 
leading to a decrease in total β-catenin and an increase in phosphorylated β-catenin, and 
suppression of β-catenin/TCF transcriptional activity [22].  
In this study, we used bioinformatics tools to identify miR-590-3p binding sites on 
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CCNG2 3’UTR.  Through reporter and functional assays, we found miR-590-3p targets 
CCNG2 and promotes β-catenin signaling.  
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MATERIALS AND METHODS  
Cell culture  
ES-2 was purchased from American Type Culture Collection (ATCC, Manassas, VA, 
USA), as previously reported [22], while SKOV3.ip1 cells were generously donated by Dr. 
Mien-Chie Hung (University of Texas M.D. Anderson Cancer Center, Huston, Texas). ES-2 
and SKOV3.ip1 cells were maintained in McCoy 5A media (Sigma-Aldrich), supplemented 
with 10% Fetal Bovine Serum (FBS), 100 IU/ml penicillin and 100μg/ml streptomycin (all 
purchased from Life Technologies). Cells were incubated in a humidified atmosphere of 5% 
CO2 at 370 C.  
  
Transient transfection 
Transient transfection of plasmids (0.25 to 1.5 µg), miRNA mimics, inhibitors or 
siRNA (150-200 nM) were carried out using Lipofectamine 2000 or Lipofectamine RNAiMAX 
(Life Technologies) following the manufacturer’s suggested procedures. Non-targeting 
negative control (NC), hsa-miR-590-3p mimic [21], and siCCNG2 [22], were purchased from 
GenePharma Co. (Shanghai, China). Anti-miR-590-3p and its corresponding NC were 
purchased from RiboBio (Guangzhou, China).  
 
Generation of mir-590 stable cell lines 
ES-2 and SKOV3.ip1 cells stably overexpressing mir-590 precursor stem-loop 
sequence were cloned into the pRNAT-CMV3.2/Hygro expression Vector (GenScript). Control 
cells (EV), were transfected with pRNAT-CMV3.2/Hygro, without the mir-590 insert, as 
previously described [21]. 
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Reagents and plasmids  
CCNG2 was cloned into a retroviral vector, pBabe-puro [38]. The virus was produced 
by co-transfecting either pBabe-FLAG-CCNG2 or pBabe-empty vector. The plasmid was then 
packaged into pUMVC, and pCMV-VSVg envelope plasmid [39]. A mutant form of β-catenin 
(S33Y) [40], which is phosphorylation and degradation resistant, was cloned into a pcDNA 
plasmid. It was obtained from Addgene (Cambridge, MA, USA).  
  
RNA extraction and real-time PCR  
Total RNA was isolated using TRIzol reagent (Invitrogen) as previously described [41]. 
To determine mRNA levels, 1.5 μg of total RNA was used to synthesize first strand cDNA by 
M-MuLV Reverse Transcriptase (New England BioLabs Ltd, ON, Canada). Real-time PCR 
was carried out using gene-specific primers and EvaGreen qPCR Master Mix (Applied 
Biological Materials, ABM). The expression levels of mRNA were normalized to GAPDH. 
The relative expression levels of mRNAs were determined using the standard 2-ΔΔct method. 
 
Protein extraction and immunoblotting  
Cells were lysed in RIPA buffer (20 mM Tris, pH 8.0, 150 mM NaCl, 10 mm NaF, 0.1% 
SDS, 1% Nonidet P-40 and 1 × protease inhibitor cocktail (Pierce, IL, USA). Cell lysates were 
then collected by centrifugation at 12,000g for 20 minutes at 4oC. Bicinchoninic acid (BCA) 
assay was conducted to measure protein concentration. An equal amount of protein samples 
was subjected to 10% SDS-polyacrylamide gel electrophoresis and transferred onto 
polyvinylidene difluoride (PVDF, Bio-Rad) membranes. The membranes were then blocked 
with 5% milk for 1 hour at room temperature followed by incubation with primary antibodies 
in milk overnight at 4oC. The membranes were washed with TBS-T and subsequently probed 
with an HRP-conjugated secondary antibody (1:5000) at room temperature for 2 hrs. Signals 
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were visualized using ECL (Millipore, ON, Canada) according to the manufacturer’s protocol. 
CCNG2 antibody was obtained from Abcam (1:500). β-catenin and p-β-catenin antibodies were 
obtained from Cell Signaling (1:1000 and 1:500 respectively) and GAPDH antibody was 
purchased from Santa Cruz (1:10000). 
  
Luciferase assay  
Luciferase constructs fragments of the CCNG2 3ʹ UTR, containing the predicted miR-
590-3p binding sites, were generated by PCR using forward primers 5′ - 
GCTGAAAGCTTGCAACTGCCGAC - 3′ and reverse primers 
5′ - GGTATCGTTGGCAGCTCAGGAAC - 3′. The resulting cDNA fragments were cloned 
into pMIR-Report (Ambion, Austin, TX, USA) downstream of the luciferase coding sequence. 
Cells were seeded in 12-well plates at a density of 75x104 cells/well and. pMIR-Report-
CCNG2 3ʹ UTR plasmids and pRL-TK internal control (encoding Renilla luciferase) plasmids 
were co-transfected. Five hours after transfection, cells were recovered in media supplemented 
with 10% FBS. 24 hours after transfection, the cells were lysed and luciferase activities were 
measured using the Dual-Luciferase Reporter Assay System (Promega, WI, USA) according 
to the manufacturer’s instructions as previously reported [42]. 
  
Spheroid formation assay (3D hanging drop) 
Spheroid formation assays were performed as described in [22]. Briefly, at 24 hours 
after transfection, cells were collected and 2x104 cells were re-suspended in 20 μl of culture 
media. 10-21 drops of cells were placed on the inside of a 100 mm culture dish cover for 3-4 
days and spheroids were photographed.  
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Migration and invasion assays  
 Migration and invasion assays were performed as previously described in [21]. Briefly, 
for migration experiments, cells were seeded onto transwell membranes at a density of 12 x103 
cells per well. To assess invasion, cells were seeded onto transwell membranes pre-coated with 
a thin layer of Matrigel, at a density of 15x103. At 24 hr after seeding, cells were fixed and 
stained.  Cells on the top of the transwell were removed by swabbing and filters were cut and 
mounted on a slide. Pictures were taken for the whole fields, and cells were counted using an 
automated quantification plugin for ImageJ [43]. 
 
TOPflash reporter assay 
To assess β-catenin-TCF/LEF transcriptional activity, the TOPflash reporter assay 
was utilized. EOC cells were transiently co-transfected with TOPflash reporter construct and 
Renilla control plasmid. The Firefly and Renilla activities were then measured using the 
Dual-Luciferase Reporter Assay System (Promega, Fitchburg, WI, USA) according to the 
manufacturer’s protocol. 
 
Statistical analysis 
All experiments were done at least three times with at least triplicates in each group. 
The results are expressed as mean ± SEM in bar graphs. GraphPad Prism 6 was used to 
perform all statistical analyses. Two groups comparison were analyzed using Student’s t-
test, while one-way ANOVA followed by Student-Newman-Keuls post hoc test was used to 
analyze multiple groups. Significance was defined as p<0.05.  
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RESULTS 
CCNG2 is a target gene of miR-590-3p 
 The 3ʹ UTR of CCNG2 harbours three predicted targeting sites for miR-590-3p (Fig. 
1A top). To determine if CCNG2 is a target gene of miR-590-3p, a CCNG2 3ʹ UTR fragment 
containing the predicted miR-590-3p target sites was cloned into the p-MIR-REPORT 
Expression Vector, downstream of the luciferase coding sequence. Cells were transfected 
with the reporter construct, together with miR-590-3p or a non-targeting control oligo (NC).  
Luciferase assays revealed that miR-590-3p decreased the luciferase activity when 
compared to NC (Fig. 3.1A bottom).  
To determine if miR-590-3p regulates CCNG2 expression, ES-2 and SKOV3.ip1 cells 
were transiently transfected with miR-590-3p or NC. Total RNA was extracted and reverse 
transcribed. As revealed by qRT-PCR, CCNG2 mRNA levels were significantly lower in cells 
transfected with miR-590-3p than in the NC group (Fig. 3.1B). Similarly, in ES-2 cells stably 
transfected with mir-590, CCNG2 mRNA levels were also significantly reduced when 
compared to cells expressing the control empty vector (EV) (Fig. 3.1C, left panel). In addition, 
Western blot analyses revealed that mir-590 downregulated CCNG2 protein levels (Fig. 3.1C, 
right).   
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Figure 3.1.  CCNG2 is a target gene of miR-590-3p. A) miR-590-3p targets CCNG2 3’UTR. 
Three predicted miR-590-3p binding sites are found in CCNG2 3’UTR. A luciferase reporter 
construct containing these CCNG2 3’UTR was generated using the pMIR-REPORT vector. 
Transient transfection of miR-590-3p significantly decreased the luciferase activity in ES-2 
cells. B) miR-590-3p downregulates CCNG2 mRNA levels. In ES-2 and SKOV3.ip1 cells 
transiently transfected with miR-590-3p, CCNG2 mRNA levels were significantly lower than 
in control cells transfected with a non-targeting oligo (NC). C) mir-590 inhibits CCNG2 
expression. CCNG2 protein (left) and mRNA (right) levels were lower in ES-2 cells stably 
overexpressing mir-590 precursor then in control cells expressing the empty vector (EV). Data 
represents mean ± SEM (n=3). ** p < 0.01, *** p < 0.001, **** 0.0001 p <  vs controls. 
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Silencing of CCNG2 mimics the effect of miR-590-3p 
To further investigate if miR-590-3p regulates cell growth by targeting CCNG2, ES-2 
cells were transfected with siCCNG2 or NC. Western blotting and qRT-PCR confirmed that 
CCNG2 protein and mRNA levels were downregulated by siCCNG2 (Fig. 3.2A). Transient 
transfection of siCCNG2 and miR-590-3p significantly increased cell proliferation when 
compared to NC (Fig. 3.2B). Similarly, transient transfection with siCCNG2 or miR-590-3p 
significantly enhanced cell migration (Fig. 3.2C) and invasion (Fig. 3.2D).   
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Figure 3.2. CCNG2 knockdown mimics the effect of miR-590-3p.  A) Confirmation of 
CCNG2 down-regulation after siRNA transfection.  ES-2 cells were transfected with a siRNA 
targeting CCNG2 or a non-targeting oligo (NC) and Western blotting (top) and qPCR (bottom) 
were performed. B) Silencing of CCNG2 or overexpression of miR-590-3p increases cell 
proliferation. ES-2 cells were transfected with siCCNG2, miR590-3p, or NC and cell numbers 
were determined at 48h after transfection. C) Silencing of CCNG2 or overexpression of miR-
590-3p increases cell migration. SKOV3.ip1 cells transiently transfected with siCCNG2 or 
miR-590-3p had a significantly higher number of migrated cells when compared to NC.  D)  
Knockdown to CCNG2 increases cell invasion. ES-2 cells transfected with siCCNG2 or miR-
590-3p had a significantly higher number of invaded cells when compared to NC.  Data 
represent mean ± SEM (n=3). ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs NC.  
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Overexpression of CCNG2 reversed the effect of miR-590-3p 
A stable cell line overexpressing CCNG2 and a control cell line expressing the empty 
vector (EV) have been generated in our lab [22]. These stable cell lines were used to determine 
whether overexpression of CCNG2 can block the effect of miR-590-3p. Cells were transfected 
with miR-590-3p or NC.  Overexpression of miR-590-3p significantly increased cell numbers 
in the control cells. However, in cells overexpressing CCNG2, the effect of miR-590-3p was 
strongly inhibited (Fig. 3.3A). Similarly, mir-590-stable cells transiently transfected with 
CCNG2 attenuated the effect of mir-590, and resulted in reduced numbers of invaded cells 
compared to the control (Fig. 3.3B).  
We have previously reported that CCNG2 disrupts the formation of compact spheroids 
in 3D hanging drop culture [22]. To determine if miR-590-3p enhances spheroid formation, 
miR-590-3p or NC were transfected into SKOV3.ip1 cells and hanging drop spheroid assays 
were performed. Cells transfected with miR-590-3p formed smaller and more compact 
spheroids compared to the ones transfected with NC (Fig. 3.3C). On the other hand, transfection 
of anti-miR-590-3p into ES-2 cells disrupted this tight formation and lead to looser spheroid 
(Fig. 3.3D). To examine whether miR-590-3p enhances the spheroid formation by targeting 
CCNG2, we transfected SKOV3.ip1 stable cells expressing the control plasmid or CCNG2 
with miR-590-3p or NC. Without CCNG2 overexpression, cells transfected with miR-590-3p 
formed very compact spheroids, when compared with cells transfected with NC. CCNG2 
overexpression resulted in the formation of loose cell aggregates and also reduced the effect of 
miR-590-3p on promoting compact spheroid formation (Fig. 3.3E). 
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Figure 3.3. CCNG2 overexpression reverses the effect of miR-590-3p. A) SKOV3.ip1 stably 
transfected with CCNG2 or its control vector, pBabe, were transiently transfected with miR-
590-3p or a non-targeting control oligo. B) Overexpression of CCNG2 reduces the effect of 
mir-590 on cell invasion. ES-2 cells stably expressing mir-590 or its empty vector (EV) were 
transiently transfected with CCNG2 or its empty vector pCMV and cell invasion was 
determined. C) 3D spheroids were formed by the hanging drop culture method. Cells were 
transfected with miR-590-3p (n=12) or D) Anti-miR-590-3p (n=21) respectively. While 
spheres formed by cells transfected with miR-590-3p were smaller in size and more compact 
compared to the control ones, anti-miR-590-3p reversed this effect. E) Overexpression of 
CCNG2 reverses the effect of miR-590-3p on the spheroid formation.  Control or CCNG2 
stable cells were transiently transfected with miR-590-3p or NC and hanging drop cultures 
were performed.  In control cells, miR-590-3p overexpression resulted in the formation of 
compact spheroids. CCNG2 stable cells formed loose spheroids and also reduced the effect of 
miR-590-3p on spheroid formation (n=13). The circumferences of spheres were measured 
using ImageJ Software. Data represent mean ± SEM (A and B) n=3. Groups significantly 
different from each other are denoted by a different letter. ** p < 0.01, *** p < 0.001 vs controls. 
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mir-590 enhances β-catenin signaling by suppressing CCNG2  
Since CCNG2 inhibits β-catenin activity [22], we investigated whether miR-590-3p 
promotes β-catenin signaling. TOPflash reporter assays were first performed to determine the 
transcriptional activity of β-catenin/TCF. In both SKOV3.ip1 and ES-2 cells, stable 
overexpression of mir-590 resulted in a significant increase in TOPflash activity (Fig. 3.4A).  
Transfection of CCNG2 significantly reduced basal luciferase levels while mir-590-induced 
luciferase activity (Fig. 3.4B).  In mir-590 cells, higher total β-catenin and lower phosphor-β-
catenin levels were observed (Fig. 3.4C).  Finally, to determine if activation of the β-catenin 
pathway contributes to the tumor-promoting effects of miR-590-3p, we transfected control and 
mir-590 stable cells with a siRNA targeting β-catenin or a NC. As shown in Fig. 3.4C, silencing 
of β-catenin reversed the ability of mir-590 cells to form tight, compact spheroids (Fig. 3.4D).  
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Figure 3.4. mir-590 enhances beta-catenin signaling by suppressing CCNG2. A) mir-590 
overexpression increases β-catenin transcriptional activity. TOPflash reporter assays were 
performed in both ES-2 and SKOV3.ip1 cells stably transfected with mir-590 or its control 
empty vector (EV). B) Overexpression of CCNG2 reduces the effect of mir-590 on β-catenin 
transcriptional activity. Control or mir-590 stable cells were transfected with CCNG2-
expressing construct or its control vector. TOPflash reporter assays were performed in ES-2 
cells. Data represent mean ± SEM (n=3). C) mir-590 overexpression slightly increases total β-
catenin but decreases phospho-β-catenin when compared to its EV control. D) Knockdown of 
β-catenin blocks the effect of mir-590 on spheroid formation. Data represent mean ± SEM 
(n=10). *** p < 0.001, **** p < 0.0001 vs controls (A). Groups significantly different from 
each other are denoted by a different letter (B).  
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DISCUSSION 
Recently, we have reported that miR-590-3p promotes EOC development via a novel 
FOXA2-VCAN pathway. In this study, we investigated additional target genes of miR-590-3p. 
Using bioinformatics tools, luciferase assays, and functional analyses, we identified CCNG2 
as a direct downstream target of miR-590-3p and demonstrate that down-regulation of CCNG2 
is in part responsible for the tumor-promoting effects of miR-590-3p.  
We have identified FOXA2 as a target gene for miR-590-3p.  Since a miRNA can target 
many genes [44, 45], we investigated additional targets for miR-590-3p in this study. Analysis 
of CCNG2 3’UTR revealed that it has three predicted binding sites for miR-590-3p. When 
CCNG2 3’UTR was inserted downstream of the luciferase gene, miR-590-3p reduced the 
luciferase activity, suggesting that miR-590-3p can bind to the CCNG2 3’UTR to inhibit the 
luciferase expression. In addition, transient or stable transfection of miR-590-3p decreased 
mRNA and/or protein levels of CCNG2. Finally, silencing of CCNG2 mimicked, while 
overexpression of CCNG2 reduced, the effect of miR-590-3p on cell proliferation, migration, 
invasion, and spheroid formation.  These findings strongly suggest that down-regulation of 
CCNG2 is also partially responsible for the tumor-promoting effects of miR-590-3p.  While 
this study is the first in EOC cells to show that CCNG2 is targeted by a miRNA, several studies 
in other types of cancer have reported that miRNAs can target CCNG2 to promote cancer 
development. For example, miR-1246 induces cell proliferation and invasion, as well as drug 
resistance, by targeting CCNG2, in breast cancer [46] and pancreatic cancer [47]. miR-135b 
has also been reported to target CCNG2 and exert tumor promoting effects in lung cancer [48].  
In addition, miR-340 promotes gastric cancer development by inhibiting CCNG2 [49].  Finally, 
miR-93 targets CCNG2 to exert tumor-promoting effects in laryngeal squamous cell carcinoma 
[50]. These findings suggest that CCNG2 is tightly regulated by miRNAs and down-regulation 
of CCNG2 by miRNAs is common to the development of many types of cancer.  
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Cancer cells possess varying capacities for spheroid formation [11, 12]. It has been 
demonstrated that more aggressive EOC cells form tighter and more compact spheroids [13]. 
In this study, we showed that cells overexpressing miR-590-3p were able to form more compact 
and much smaller spheroids than the control cells while anti-miR-590-3p disrupts this cell 
aggregation and compaction. On the other hand, overexpression of CCNG2 reversed this effect. 
These findings, together with our previous studies, which show that miR-590-3p promote EOC 
cell proliferation, migration, and invasion in vitro and tumor growth and metastasis in vivo, 
strongly support the notion that miR-590-3p may exerts its tumor-promoting effects, at least in 
part, by targeting CCNG2 in EOC.  
The Wnt/β-catenin signaling plays critical roles in carcinogenesis and the 
development of various types of cancers; including colorectal cancer [51], liver cancer [52], 
leukemia [53], melanoma [54], breast cancer [55] and ovarian cancer [56-58]. Although it 
was initially believed that aberrant β-catenin level is mainly reported in the endometrioid 
subtype of EOC, accumulating evidence suggests its role in the development of other 
subtypes, including serous ovarian cancer [22, 59]. In a previous study, we showed that 
CCNG2 overexpression decreased the levels of both DVL2 and LRP6 in EOC cells, and 
hence, indirectly promoted β-catenin phosphorylation and degradation [22].  In this study, 
we found that miR-590-3p reduced phosphorylated β-catenin levels and enhanced the 
transcriptional activity of β-catenin/TCF, as revealed by Western blotting and TOPflash 
Luciferase assays, respectively. Interestingly, overexpression of CCNG2 attenuated the 
stimulatory effects of miR-590-3p on TOPflash luciferase activity, suggesting that miR-590-
3p enhances β-catenin signaling by down-regulating CCNG2. Furthermore, we found that in 
mir-590 stable cells, knock-down of β-catenin by siRNA reduced the ability of cells to form 
tight spheroids. These results suggest that activation of β-catenin contributes to the tumor-
promoting effects of miR-590-3p.  Recently, DKK1, an antagonist of the Wnt/ β-catenin 
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pathway, has been reported to be a miR-590-3p target gene [60].  In the mir-590 cells, we found 
that DKK1 levels were down-regulated [21].  It is possible that miR-590-3p also targets DKK1 
to enhance β-catenin signaling. This will be investigated in the future. 
In summary, we provide, for the first time to our knowledge, evidence to support that 
miR-590-3p promotes EOC progression, in part by inhibiting CCNG2 expression and inducing 
β-catenin signaling. In addition, our results shed light on a new role for miR-590-3p in 
modulating β-catenin signaling in EOC tumorigenesis. 
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CHAPTER 4 
SUMMARY AND FUTURE DIRECTIONS 
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SUMMARY 
The objectives of my PhD were to investigate the function of miR-590-3p in human 
ovarian cancer cells and to determine the mechanisms of miR-590-3p actions.  
Aim 1: To investigate the role of miR-590-3p in ovarian cancer cells 
To understand the role of miR-590-3p in ovarian tumor development, we first 
investigated the level of miR-590-3p in human ovarian clinical samples.  We found that miR-
590-3p was significantly elevated in high-grade EOC tumors when compared with normal 
ovaries or lower grade tumors. In addition, miR-590-3p plasma level was higher in EOC 
patients than in subjects with benign gynecological disorders (Chapter 2).  These findings 
suggest that increased expression of miR-590-3p in ovarian tumors is associated with a more 
aggressive phenotype.  
To examine the function of miR-590-3p in ovarian cancer cells, gain- and loss-of 
function approaches were used. In EOC cell lines stably overexpressing mir-590, a precursor 
of miR-590-3p, we noticed a significant increase in cell proliferation, migration, invasion, and 
colony formation when compared to cells expressing a control vector (Chapter 2). Furthermore, 
we examined the ability of mir-590 stable cells to form spheroids using the hanging drop assay. 
A previous study showed that there is a direct relation between cell invasive behaviour and how 
compact the sphere is [1]. We found that mir-590-overexpressing cells formed tighter spheroids 
when compared to the control (Chapter 3). Similar results were obtained when cells were 
transiently transfected with miR-590-3p mimics.  Conversely, cells transfected with anti-miR-
590-3p decreased cell proliferation, migration, and invasion.  Together, these in vitro assays 
provide evidence that miR-590-3p exerts a tumorigenic effect in ovarian cancer cells.  
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To further confirm that tumor-promoting effects of miR-590-3p on EOC, in vivo studies 
were carried out.  To examine the effect of mir-590 on tumor formation, we injected mir-590-
overexpressing cells or its control cells subcutaneously into nude mice. Results from this 
experiment showed that mice injected with mir-590 cells formed significantly larger tumors. 
To investigate the effects of mir-590 on tumor metastasis, mice were injected intraperitoneally 
with mir-590-overexpressing or control cells.   Mice inoculated with mir-590 cells formed more 
nodules and disseminated more within the peritoneal cavity compared to those injected with 
control cells. These results support a tumor-promoting role of mir-590 in EOC development. 
Aim 2: To determine the mechanisms by which miR-590-3p exerts its tumorigenic effects  
To explain the mechanism of miR-590-3p action, we examined the molecular events 
altered in stable cells overexpressing miR-590-3p using cDNA microarray and bioinformatics 
tools.  We identified two pathways, FOXA2/VCAN and CCNG2/β-catenin that mediate effects 
of miR-590-3p.  
Firstly, using cDNA microarray, we identified FOXA2 as one of the most strongly 
down-regulated genes by mir-590.  We further demonstrated, by luciferase reporter assays, real-
time PCR and Western blotting, that miR-590-3p directly targets FOXA2.  In addition, we 
found that FOXA2 level was greatly down-regulated in high-grade EOC tumors compared to 
low malignancy potential ones.   Moreover, knockdown of FOXA2 by siRNAs or knockout of 
FOXA2 by CRISPR/Cas9 resulted in an increase in cell proliferation, migration and invasion. 
On the other hand, overexpressing FOXA2 in mir-590 stable cells reduced the tumor-promoting 
effects of mir-590. These findings demonstrate that the tumor-promoting effects of miR-590-
3p is mediated, in part by inhibition of FOXA2. 
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We also identified a novel relationship between FOXA2 and VCAN. We showed that 
FOXA2 inhibition by either knockdown or knockout enhanced, while overexpression of 
FOXA2 reduced, VCAN expression. Moreover, we found that VCAN promoter and intragenic 
DNA has FOXA2 predicted binding sites. Results from ChIP-qPCR showed enrichments of 
VCAN DNA in the regions where FOXA2-binding sites were predicted when compared with 
the IgG group. This is in agreement with the expression patterns of FOXA2 and VCAN in EOC 
tumor samples from the TCGA database where we observed a negative correlation between 
FOXA2 and VCAN mRNA levels. These results strongly suggest that FOXA2 is a 
transcriptional repressor of VCAN.  
Interestingly, in the same tumor samples, we found that low VCAN and high FOXA2 
mRNA levels were associated with longer survival in ovarian cancer patients. In addition, 
knockdown of VCAN by siRNA led to inhibition of EOC cell proliferation, migration and 
invasion. These findings support the nation that VCAN has tumor-promoting effects in, while 
FOXA has a tumor suppressing effect in ovarian cancer. 
Another miR-590-3p target genes identified in this study is CCNG2.  Combined results 
from different miRNA target search engines revealed three potential target sites for miR-590-
3p on the 3ʹUTR of CCNG2. Luciferase assay for cells co-transfected with miR-590-3p and a 
construct carrying the potential target sites showed a significant decrease in luciferase activity 
when compared to control cells. In addition, we noticed a decrease in CCNG2 mRNA and 
protein levels in the cells overexpressing miR-590-3p or its precursor.  
Previous studies showed that CCNG2  inhibits cell proliferation, migration and invasion 
[2]. Silencing of CCNG2 using siRNA mimicked the effect of miR-590-3p and increased EOC 
cell proliferation, migration and invasion, while CCNG2 overexpression reduced the effect of 
miR-590-3p and decreased cell proliferation and invasion rates in EOC cells. In addition, 
hanging drop assays revealed that cells overexpressing CCNG2 formed much looser spheroids 
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compared to control cells, consistent with our previous findings that CCNG2 has anti-tumor 
function in EOC.  
We previously showed that CCNG2 attenuates β-catenin transcriptional activity in 
EOC cells [2]. In this study, we examined the effect of miR-590-3p to on β-catenin 
signaling. We found that mir-590 reduced the phosphorylated level of β-catenin and 
significantly increased the transcriptional activity of β-catenin/TCF in luciferase reporter 
assays. Interestingly, overexpression of CCNG2 reduced the stimulatory effect of mir-590 on 
β-catenin/TCF transcriptional activity.  Finally, in spheroid formation assays, we showed 
that when siRNA targeting β-catenin was transfected into mir-590 stable cells, the ability of 
mir-590 cells to form tight spheroids was reduced.  These findings suggest that the CCNG2/ 
β-catenin pathway also mediates the effect of miR-590-3p on EOC development. 
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FUTURE DIRECTIONS 
To further investigate the role of mir-590 in EOC  
In the future, we would like to further investigate how miR-590-3p may regulate the in 
vivo progression of EOC tumors. Since our data suggest that miR-590-3p increase migration 
and invasion, it is likely that miR-590-3p may increase early dissemination of cancer cells. To 
better understand both primary and secondary tumor formation, we would like to pursue the in 
vivo study by implementing an orthotopic technique. Instead of injecting ovarian cancer cells 
subcutaneously or intraperitoneally, cells will be injected under the ovarian bursa. Using this 
assay will increase our understanding and assessment of how miR-590 overexpression 
regulates the formation of primary lesions, as well as ascites accumulation and cell spreading 
throughout the peritoneal cavity to mimic the disease in humans. 
We would like to investigate the role of miR-590-5p in the malignant transformation of 
ovarian cancer. The tumor-promoting effects of mir-590 overexpression observed in our study 
could also be attributed to miR-590-5p overexpression. Our preliminary results showed that 
both anti-miR-590-3p and anti-miR-590-5p attenuated the effect of mir-590, suggesting that 
miR-590-5p is also playing a role in EOC development but further investigation is needed in 
the future. 
The Wnt/β-catenin pathway is critical in maintaining cancer stem cells (CSCs) [3, 4].  
Since mir-590 increases β-catenin signaling, it will be interesting to investigate if miR-590-3p 
and/or miR-590-5p play a role in CSC self-renewal.  Previous studies suggested that both 
cancer and stem cells share common cellular mechanisms and characteristics [5, 6]. Some of 
these common characteristics are the ability of both cell types to proliferate continuously, to 
stay viable in suspension culture as well as the ability to form spheroids [7]. Many stem markers 
include: CD44, CD133, CD24, SOX2, NOTCH3 and ALP, have been utilized to measure the 
level of stemness in ovarian tumor-initiating cells, or ovarian cancer stem-like cells (CSLCs) 
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[8].  In the future, we will investigate whether mir-590 is contributing to the process of ovarian 
cancer development by promoting CSLCs stemness.  
 
To further investigate the mechanisms of mir-590 actions in EOC  
 In our cDNA microarray, we found that a number of genes are up- or down-regulated 
by mir-590 overexpression.  For example, we found that DKK1, which was reported to be 
targeted by miR-590-3p in colon cancer [9], was strongly downregulated in our mir-590 cells. 
In the future, we will investigate the role of miR-590-3p in promoting stemness and in 
regulating DKK1. Stemness-induced sphere formation assays will be performed in the mir-590 
stable cells transfected with either DKK1 expression plasmid, or siDKK1 oligo. Results from 
these experiments will shed more light on the functional role of mir-590 in inducing stemness 
and regulating β-catenin during ovarian cancer development.  
 
CONCLUSION 
The present work provides evidence that miR-590-3p has a tumor-promoting effects by 
targeting FOXA2 and CCNG2 in ovarian cancer (Fig. 4.1). We also characterized a novel 
tumor-suppressive role of FOXA2 in EOC through the inhibition of VCAN expression. In 
addition, our microarray analysis has identified DKK-1, a known Wnt/β-catenin signal 
inhibitor, as one of the downregulated genes in cells overexpressing mir-590. All together, these 
targets affect several major downstream mediators that contribute to the development and 
progression of ovarian cancer disease.   
 
 
 
 
136 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 4.1. Proposed summary model for the role of mir-590 in promoting EOC 
development. The levels of miR-590-3p were significantly elevated in high-grade EOC 
tumours and serum clinical samples. miR-590-3p targets the 3ʹUTR of FOXA2 mRNA and 
inhibits its translation, while increasing VCAN levels. In addition, miR-590-3p targets the 
3ʹUTR of CCNG2 mRNA leading to an increase in β-catenin level. DKK-1, the Wnt/β-catenin 
suppressor, was also predicted to have a target site for miR-590-3p. These events cascade leads 
to a promotion of EOC cell proliferation, migration, invasion and metastasis. 
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